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ABSTRACT
NATALIE MAURISA STRAIGHT MCGUIER. A Role for Kv7 Channels in Alcohol Consumption:
Genetics, Drinking Behavior, and Neuroadaptations. (Under the direction of PATRICK J.
MULHOLLAND)
Alcohol use disorder (AUD) is a major public health issue that produces
enormous societal and economic burdens. Current FDA-approved pharmacotherapies
for treating AUD suffer from deleterious side effects and are only effective in a subset of
individuals, representing a need for improved medications for the management of AUD.
The experiments described in this dissertation provide evidence for a complex
relationship between Kv7 channels and alcohol-related behaviors that spans genetics,
behavioral pharmacology, and biochemical adaptations suggesting these channels are a
target for treating AUD. We first examined the genetic relationship between Kcnq genes
and alcohol-related behaviors, showing that these channels contribute to an alcohol
drinking phenotype. Behavioral pharmacology studies strengthened this relationship by
showing that systemic administration and microinjections of retigabine, an FDAapproved anticonvulsant and Kv7 channel positive modulator, to components of the
addiction neurocircuitry reduced voluntary consumption in a long-term intermittent
access model in an alcohol-specific manner. Finally, we investigated alcohol-induced
neuroadaptations in the nucleus accumbens (NAc). Specifically, we observed that longterm drinking enhanced sensitivity to the pro-convulsant effects of Kv7 channel
blockade, altered surface trafficking of Kv7.2 channels between detergent resistant and
soluble membranes, and reduced Kv7.2 channel SUMOylation in the NAc. To our
knowledge, these data are the first to show evidence for post-translation modification by
SUMOylation in a model of alcohol or drug exposure. Altogether the work presented in
this dissertation indicates that retigabine may be a promising treatment for AUD, and
that Kv7 channels are a target of alcohol-induced neuroadaptations.
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CHAPTER 1: INTRODUCTION
Millennia of Alcohol Use in Global Cultures
The purposeful creation and consumption of alcohol is as ancient as the first
known civilization. Our Stone Age ancestors left behind jugs intentionally meant for
fermentation dating back to 10,000 BC (Patrick, 1970). This time period, the Neolithic
Revolution, represents a shift from nomadic wandering to an agricultural-based lifestyle.
Some anthropologists speculate that the demand for beer inspired farming in the Near
East as mass beer consumption preceded the baking of bread (Braidwood, 1953; Katz,
1987). Throughout ancient history alcohol consumption was integrated into nearly every
growing civilization. Between 4000 and 3500 BC wine is clearly indicated in Egyptian
hieroglyphics, and alcohol use was an important part of societal exchange as well as
religion (Cherrington, 1930; Darby, 1977; King, 1947). By 3000 BC alcohol consumption
was a mainstay in the Greek, Roman, and East Asian cultures as well; it was engrained
throughout the entirety of the known world.
Due in no small part to the psychoactive effects of alcohol, by 700 BC it was a
central part of nearly every major religion, although in the centuries that followed most
religions and governments would condemn excessive use and drunkenness (Dietler,
2006). Greeks and Romans worshiped gods dedicated to wine and merriment (Sournia,
1990), and when old deities gave way to new in the first and second centuries BC and
AD, sacramental wine and beer brewing were at the heart of Jewish and Christian
traditions (Raymond, 1927). In a time span that held the birth of Christianity, the Dark
Ages of Europe, and its Renaissance many clergy considered beer and wine a necessity
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to worship. These traditions were maintained until the 1800s when a social and
economic shift spurred Protestant Christians in both Western Europe and America to
demand complete abstinence from alcohol (Esteicher, 2006).
In the 19th century, industrialization took hold of the economy of the United
States. The increased number of factory positions lead to an influx of formerly rural
families to cities. The isolation and cyclical farming work schedule allowed for excessive
drinking in rural culture. In contrast, city living was more regimented, which lead to
unease with routine drunkenness among factory workers (Dietler, 2006). In the years
following the Civil War saloons became increasingly popular in urban areas and
synonymous with prostitution, gambling, and other amoral acts (Rorabaugh, 1979).
Additionally rural and urban women began to seek safety for themselves and their
children from alcohol-induced domestic violence, wage loss, and child neglect (Blocker,
2006). These are the first recorded examples of what would now be diagnosed as
alcohol use disorder (AUD). Soon the Protestant church joined the outcry against
drinking, and, as a moral and religious crusade, the Temperance Movement was born
(Hill, 2004). By 1919 most states in the US had independently banned the sale and
consumption of alcoholic substances, however prohibition was formalized at a federal
level with the ratification of the 18th amendment, banning the sale of intoxicating
beverages with an alcohol content greater than 0.5%.
During the Temperance Movement and prohibition, alcohol consumption per
capita was reduced by an estimated 20% in the US (Blocker, 2006). This moderate
reduction represents almost the entirety of the success of prohibition. The illegality of
alcohol lead to an increase in the consumption and sale of unregulated homemade
liquor. Underground bars known as speakeasies replaced saloons, and arguably the
most disastrous consequence of prohibition was the formation of organized crime
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syndicates that continue to exist today. Prohibition was repealed by the 21st amendment
in 1933 as a means of stimulating the economy during the Great Depression. While most
regard Prohibition as a misadventure, its failure to induce national abstinence
exemplifies how engrained alcohol consumption is in our way of life (Blocker, 2006).
Furthermore, the social outcry against alcohol abuse that spurred the Temperance
Movement revealed the necessity of understanding and treating alcohol addiction as a
disease.
Lawmakers have discarded the idea of banning alcohol sales and consumption,
however, the substance is heavily regulated at both the state and federal levels,
including laws ranging from the regulation of sales to minimum drinking ages. In the
1940s National Council on Alcoholism was created to promote the disease theory of
alcoholism (NCADD, 2015), and in 1968 the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) was formed with the mission statement “to promote, direct and
support biomedical and behavioral research on the causes, consequences, treatment,
and prevention of alcoholism and alcohol-related problems” (NIAAA, 2012). Numerous
other organizations have since formed to alleviate the personal and social
consequences of alcoholism. In the present day, clinicians and researchers recognize
alcohol abuse as an addictive brain disorder that should and can be medically treated.

Prevalence of Alcohol Use Disorder
Alcohol consumption is pervasive in the United States. 51.3% of adults selfreport as regular drinkers (>12 drinks in the previous year) and an additional 12.9%
report as infrequent drinkers (1-11 drinks in the past year) (Blackwell DL, 2012). 12% of
adults will face alcohol use disorder (AUD) at some point in their lives, which the NIAAA
defines as a diagnosable medical condition wherein an individual’s drinking causes
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distress or harm (NIAAA, 2012). The condition is characterized by unhealthy or
dangerous drinking habits (alcohol abuse), and by symptoms of alcohol dependence
including a forfeit of normal life function in favor of the pursuit of alcohol. AUD comes at
a tremendous societal and personal cost. Annually, 15,990 individuals die from alcoholic
liver disease, 25,682 die from alcohol-induced deaths (excluding accidents and
homicides), and 10,228 people die in alcohol-impaired driving crashes (Corrao G, 2004;
LA, 1998; Rehm and Gmel, 2003). Furthermore, in 2006 the Center for Disease Control
estimated that excessive alcohol consumption in the United States cost approximately
$223.5 billion in expenses related to losses in workplace productivity, healthcare,
criminal justice, and motor vehicle accidents (Bouchery EE, 2011). Considering these
extreme costs it is obvious that effective, accessible, and inexpensive treatment options
for AUD are desperately needed.

Past and Present Treatment Options
There are four key points of treatment when approaching any drug of abuse: 1)
intervention to decrease the rewarding value of drugs, 2) increase the value of
endogenous rewards while establishing alternative behaviors, 3) to weaken drugassociated responses through behavioral treatments such as extinction learning, and 4)
to strengthen executive control through cognitive therapy (Volkow et al., 2003). Several
accepted treatment options for AUD exist that target multiple points of intervention.
Cognitive and behavioral psychological therapy are perhaps two of the most utilized, and
aim to establish healthier behaviors and avoid trigger recognition. Group therapy (e.g.
Alcoholics Anonymous; AA) is often the first form of intervention for treatment-seeking
patients with AUD. Interestingly, a Cochrane review found no experimental studies that
unequivocally demonstrated the effectiveness of AA or similar twelve-step approaches
	
  

4	
  

(Ferri et al., 2006). In addition, individuals may hesitate to initiate twelve-step programs
because they require immediate cessation from alcohol, which can result in the
debilitating symptoms of alcohol withdrawal syndrome. One-on-one psychological
counseling in the form of motivational interviewing (MI) and motivational enhancement
therapy (MET) developed as a direct result of this hesitation by addicts (Woody, 2003).
While beneficial for the subset of individuals who would otherwise resist group programs,
MI and MET on their own are not as efficacious as twelve-step programs for the majority
of

patients.

Psychological

interventions

are

frequently

used

in

concert

with

pharmacological interventions to ease the physiological symptoms of addiction. Indeed,
multi-faceted approaches to treatment are shown to be the most efficacious (Anton et
al., 2006; Donovan et al., 2008). However, the risks and benefits of pharmacotherapies
must also be taken into account.
Pharmaceutical treatments for AUD act at two discrete points in the addiction
process: to prevent relapse or to aid in drinking cessation. Presently there are four major
FDA-approved pharmaceuticals for AUD: benzodiazepines, naltrexone, disulfiram, and
acamprosate.

Benzodiazepines
Benzodiazepine refers to a class of drugs that contain a benzene ring fused to a
diazepine ring. Presently, the two most commonly prescribed are diazepam and
chlordiazepoxide. These compounds enhance GABAA receptor activity resulting in
sedative, anxiolytic, and anticonvulsant properties (Browne and Penry, 1973).
Benzodiazepines are used to prevent relapse by reducing withdrawal symptoms, which
can include headache, nausea, tremors, seizures, hallucinations, and death (Bayard et
al., 2004; Mayo-Smith and Bernard, 1995; Myrick et al., 2000; Myrick et al., 2009).
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However, like chronic alcohol, prolonged exposure to benzodiazepines can lead to a
hyperexcitable state and subsequent seizures (Allison and Pratt, 2003). Consequently, if
treated with this class of drug, relapse is often more severe and detrimental than if
pharmacological intervention had not been utilized (Malcolm et al., 1993; Malcolm,
2003). Additionally benzodiazepines are addictive and have a variety of adverse side
effects that include hypotension, decreased cognitive function, and anhedonia (Vgontzas
et al., 1995). Thus, while effective at reducing acute withdrawal symptoms,
benzodiazepines have serious long-term consequences making them a non-ideal choice
for treating AUD.

Naltrexone
In 1994 the FDA approved naltrexone for the treatment of alcoholism. This mu
and kappa opioid receptor antagonist has had the most clinical success; being most
effective in individuals who have already ceased drinking and seek to prevent a slip of
alcohol use from becoming full-blown relapse. While beneficial, naltrexone has been
found to be most efficacious in carriers of the A118G polymorphism on the µ-opioid
receptor gene OPRM1 (Anton, 2008; Anton et al., 2012; Schacht et al., 2013). These
studies suggest that genetic factors contribute to alcohol and drug abuse, and that
naltrexone is not necessarily beneficial to the entire population of AUD patients.
Furthermore, this drug hosts a myriad of side effects including anhedonia,
nausea/vomiting, and muscle pain (Streeton and Whelan, 2001). Although it is
considered the best available pharmaceutical treatment for aiding alcohol abstinence, it
leaves much to be desired.
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Disulfiram
Disulfiram is another FDA-approved treatment for AUD, and acts by inhibiting a
portion of the alcohol and dopaminergic metabolic pathways (Goldstein et al., 1964;
Sauter et al., 1977; Sauter and Wartburg, 1977). Alcohol is catabolized by alcohol
dehydrogenase to acetaldehyde. Acetaldehyde is a toxin that induces nausea, dizziness
and headaches before it is further metabolized into acetate. Disulfiram inhibits aldehyde
dehydrogenase, causing a build up of acetaldehyde and subsequent illness when
alcohol is consumed. Unsurprisingly, patient compliance is a tremendous obstacle in the
efficacy of this treatment. One study (Fuller et al., 1986) estimated that only 20% of
subjects followed the prescribed drug regimen. Consequently, disulfiram leaves much to
be desired in an AUD pharmacotherapy.

Acamprosate
The fourth major pharmacological treatment for alcoholism is acamprosate
(Campral). This drug is believed to enhance GABAergic reception and transmission
while reducing glutamate signaling at NMDA receptors, which are both oppositely
affected by chronic ethanol exposure (Reilly et al., 2008). Acamprosate likely
counteracts the hyperexcitable state in the central nervous system produced by
repeated bouts of alcohol exposure and withdrawal (Becker, 1996, 1998; Becker and
Hale, 1993). Acamprosate has been efficacious in preventing relapse, but yields small
effect sizes. In addition, this drug appears to be most useful to patients who have
already withdrawn from alcohol, and consequently does not aid with immediate
abstinence (Bouza et al., 2004). A recent publication using multiple rodent models of
alcohol exposure suggests that the calcium cation in the salt form of acamprosate is the
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active moiety (Spanagel et al., 2014). While the results from this study need to be
replicated, it suggests that acamprosate may not be a suitable treatment for AUD.

Together, these pharmaceuticals leave an opening for drugs that will have high patient
compliance, non-deleterious side effects, and that will help patients abstain immediately
from alcohol.

Advent of Anticonvulsants as Pharmacotherapies
Chronic alcohol consumption with episodes of withdrawal leads to an imbalance
of excitatory regulation in the central nervous system. Simply, chronic intermittent
alcohol exposure increases excitatory mechanisms (i.e. glutamate receptors, Ca2+
channels) and decreases inhibitory mechanisms (i.e. GABA receptors) (Alele and
Devaud, 2007; Gass and Olive, 2008; Szumlinski et al., 2007). This allostatic state of
brain function is believed to be a compensatory mechanism to counterbalance the
depressive effects of alcohol (Mulholland and Chandler, 2007). These effects are
visually perceived in alcohol withdrawal syndrome (AWS) where seizures and delirium
tremens are common characteristics. Given the similarity of alcohol withdrawal and its
biochemical effects to epilepsy, it is unsurprising that since 1976 clinicians have been
using anticonvulsants to treat AWS. In the past 10 years, there has been a significant
amount of interest in the use of anticonvulsants for the reduction of alcohol-seeking
behavior (Ait-Daoud et al., 2006; Book and Myrick, 2005; Malcolm et al., 2001). The
following sections highlight some of the preclinical and clinical evidence regarding the
more recent anticonvulsants to emerge as candidates to aid in drinking cessation.
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Topiramate
Topiramate is perhaps the most widely studied anticonvulsant drug in rodent
models of alcohol drinking. It is thought to have a variety of molecular targets including
voltage gated sodium channels, high voltage gated calcium channels, and GABAA
receptors (Porter et al., 2012). Regimes of systemic and acute dosing effectively reduce
drinking in alcohol-preferring rodent strains (Farook et al., 2009; Gabriel and
Cunningham, 2005; Nguyen et al., 2007). However, evidence suggests that low doses of
topiramate can increase drinking (Gabriel and Cunningham, 2005), and that the drug is
ineffective at reducing drinking in rat strains not specifically bred for high levels of
alcohol consumption (Hargreaves and McGregor, 2007).
Clinically, topiramate has been the subject several studies investigating its ability
to aid in alcohol abstinence after cessation (for a complete review see (Kenna et al.,
2009)). In an open-label trial in India, topiramate was significantly more effective at
maintaining abstinence than Disulfiram (De Sousa et al., 2008). Two double blind,
placebo-controlled studies indicate that topiramate is effective at decreasing the number
of heavy drinking days and the number of drinks per day in AUD patients (Johnson et al.,
2003; Johnson et al., 2007). However patients have experienced substantial negative
side effects including difficulty concentrating, taste perversion, and anorexia (Johnson et
al., 2007). In addition, topiramate appears to be most efficacious in individuals with a
specific GRIK1 polymorphism (Kranzler et al., 2014). Together the preclinical and clinical
data indicate that topiramate may be useful to help heavy-drinking individuals abstain
from alcohol, but there are potentially severe negative side effects.
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GABA Analogues
Gabapentin and pregabalin have a similar structure to the amino acid γaminobutyric acid (GABA), but have potent anticonvulsants actions mediated through
voltage-sensitive Ca2+ channels (Stephen and Brodie, 2011). Recent evidence in a
variety of rat drinking models indicates that gabapentin can reduce voluntary alcohol
consumption, operant responding for alcohol, and cue-induced reinstatement (Roberto
et al., 2008). Treatment with pregabalin also can reduce cue-induced reinstatement of
alcohol-seeking behavior (Stopponi et al., 2012). Similar to gabapentin and pregabalin,
vigabatrin (gamma-vinyl-GABA) is an analogue of GABA, however, vigabatrin influences
excitability by inhibiting GABA transaminase (Rogawski and Loscher, 2004). Two studies
that used a standard choice model demonstrated that vigabatrin reduced alcohol
consumption in alcohol-preferring rats. More recently Griffin et al reported that vigabatrin
decreased operant responding for alcohol as well as home cage drinking in mice (Griffin
et al., 2012; Stromberg et al., 2001; Wegelius et al., 1993).
Several small, open-label studies indicate that gabapentin can reduce withdrawal
symptoms (Bonnet et al., 2007; Myrick et al., 1998). Double blind, placebo-controlled
studies investigating the anticonvulsant’s ability to reduce drinking have contradicting
results. A study investigating consumption in moderate-drinking patients found no effect
of gabapentin (Myrick et al., 2007) whereas one investigating the same effect in heavydrinking individuals found gabapentin to be efficacious (Furieri and Nakamura-Palacios,
2007). Pregabalin helped detoxified patients remain abstinent and reduced craving and
withdrawal symptoms in small open-label trials (Di Nicola et al., 2010; Martinotti et al.,
2008). However, a double blind trial comparing naltrexone to pregabalin indicated no
difference in efficacy between the two (Martinotti et al., 2010). Finally, little is known
clinically of vigabatrin, but one open-label study suggests that it may be beneficial in
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treating the symptoms of alcohol withdrawal (Stuppaeck et al., 1996). In summary the
GABA analogues need further investigation to assess their clinical efficacy.

Levetiracetam
The exact mechanism through which levetiracetam acts is unknown, however
there is evidence to suggest that it inhibits neurotransmitter release by interacting with
the synaptic vesicle glycoprotein SV2A (Lynch et al., 2004). Only two preclinical studies
have examined the effects of levetiracetam on alcohol-related behaviors. In a voluntary
alcohol consumption model, repeated doses of levetiracetam significantly reduced
alcohol intake and preference for alcohol in rats (Zalewska-Kaszubska et al., 2011). In
the second study, levetiracetam blocked the ability of alcohol to reduce intracranial selfstimulation in mice (Robinson et al., 2013).
While preclinical studies suggest that levetiracetam is a strong candidate for
treating AUD, there is little clinical evidence to support the use of this anticonvulsant.
Three double-blind placebo-controlled studies in medium to high drinking patients
showed no effect of the levetiracetam on withdrawal symptoms, an inability to reduce the
number of drinks consumed per day, and an inability to reduce relapse (Fertig et al.,
2012; Richter et al., 2012; Richter et al., 2010). Together these studies indicate that
levetiracetam may not be a suitable treatment for AUD.

Zonisamide
Zonisamide is approved for the treatment of partial onset seizures, although its
mechanism of action is not well characterized. The drug is believed to block sodium and
T-type calcium channels, and is known to modulate glutamatergic and GABAergic
neurotransmission (Leppik, 2004; Mimaki et al., 1990; Ueda et al., 2003). One study has
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shown that a relatively high dose of zonisamide (50 mg/kg) was able to reduce alcohol
consumption, but only when the drug was actively on board (Knapp et al., 2007).
Furthermore, chronic treatments with zonisamide lead to weight loss in rodents.
There have been few clinical trials investigating the effectiveness of zonisamide
on preventing alcohol consumption. In open-label trials, zonisamide reduced craving and
consumption of alcohol-dependent patients (Knapp et al., 2010; Rubio et al., 2010). In
one placebo-controlled study the drug also reduced alcohol consumption and the urge
drink, but failed to increase the number of completely abstinent days (Arias et al., 2010).
Zonisamide also suffers from several deleterious side effects including anorexia,
depression, memory impairment, and dizziness (Services, 2013) suggesting that it may
not be advantageous for patients with AUD.

While many of these anticonvulsants show promise as therapeutics for aiding in alcohol
abstinence, most have side effects so adverse as to raise concern over patient
compliance and quality of life during treatment, or are simply not performing well in large
clinical trials. Most anticonvulsants primarily function to dampen glutamatergic signaling,
potentiate GABAergic signaling or block voltage-gated sodium channels (White, 1997).
Often when treating epilepsy, medical professionals take a multi-hit approach and
prescribe multiple drugs that act through different mechanisms (Bianchi et al., 2009;
LaFrance and Devinsky, 2004). Thus, there is a constant demand for new
anticonvulsants that act at novel targets. One such drug, retigabine, functions to open
Kv7 channels, a voltage-gated class of K+ channels (Tatulian et al., 2001; Wickenden et
al., 2000). Neither retigabine nor Kv7 channels are well understood in the context of
alcohol exposure; however, recent studies and the pharmacokinetics of both retigabine
and Kv7 channels provide exciting implications for alcohol research.
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Retigabine: Anticonvulsant and Kv7 Channel Positive Modulator
The FDA approved retigabine in 2011 for the treatment of partial onset seizures.
This anticonvulsant primarily acts as a Kv7 channel positive modulator, leading to an
increase in K+ current (Tatulian et al., 2001; Wickenden et al., 2000), and subsequent
neuronal inhibition. Positive modulation of Kv7 channels effectively reduces seizures
both preclinically and clinically (Armand et al., 1999; Brodie et al., 2010; French et al.,
2011; Porter et al., 2007). Retigabine has a mean terminal half-life of approximately 8
hours in humans, with a maximal plasma availability of 420 ng/mL 2 hours after oral
administration. In rats, the half-life is also approximately 2 hours after oral dosing
(Review: (Mazarati et al., 2008)). A 20 mg/kg systemic dose of retigabine in mice results
in a brain concentration of 2.7898 µM (Zhou et al., 2015). The side effects of retigabine
are relatively minimal and include dizziness, confusion, fatigue, dysarthria, vision
impairment and nausea. These effects are only experienced by 1-12% of patients taking
600 mg of the drug per day, and are reported as tolerable (Crean and Tompson, 2013;
Mazarati et al., 2008). 350 mg is effective at reducing seizures in humans whereas 2.5 30 mg/kg reduces convulsant activity in a variety of rodent models of epilepsy (Large et
al., 2012).
Pharmacokinetic studies of retigabine and Kv7 channels indicate that it has an
IC50 of 0.6 ± 0.3 µM to 5.2 ± 0.9 µM depending on the Kv7 channel subunit or subunit
combination being examined (Tatulian et al., 2001). Importantly, this anticonvulsant only
modulates Kv7 channel subunits expressed in the CNS (Kv7.2-Kv7.5). Retigabine
produces a hyperpolarizing shift of the activation curve of Kv7 channels by up to 40 mV,
greatly increasing the open probability of the channel around the resting membrane
potential (Tatulian et al., 2001). This suggests that Kv7 channel positive modulators may
reduce drinking and alcohol withdrawal-associated seizures in a manner similar to other
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anticonvulsants.

Additionally,

activation

of

Kv7

channels

can

influence

DA

neurotransmission in the VTA and NAc. Retigabine has been shown to inhibit basal DA
synthesis, reduce extracellular DA levels when striatal DA uptake is inhibited, and block
depolarization-induced DA release from striatal terminals (Hansen et al., 2008). Given
the importance of DA release in addiction (Kalivas, 2002), these studies suggest that
retigabine and Kv7 channel activation could influence addictive behaviors.

Kinetics and Regulation of Kv7 Channels
The Kv7 family of voltage-gated potassium channels consists of 5 subunits,
Kv7.1-Kv7.5, encoded by the genes Kcnq1-5. Four subunits come together to form the
channels responsible for M-current in peripheral organs and brain (Jentsch, 2000;
Selyanko et al., 2002; Wang et al., 1998). Kv7.1-containing channels are exclusively
expressed in the heart, whereas Kv7.2-Kv7.5 are found abundantly in the CNS. Kv7.2
and Kv7.3 subunits are the most widely distributed and are found in the cortex, basal
ganglia circuitry, hippocampus, cerebellum, thalamus, hypothalamus, and amygdala.
Kv7.3 has the next highest expression level, having been reported in the cortex,
striatum, and hippocampus (Kharkovets et al., 2000; Wang et al., 1998). In contrast,
Kv7.4 channels appear to be restricted to the VTA and dopaminergic neurons in the SNC
(Kharkovets et al., 2000). Typically, the subunits come together in dimer pairs of
Kv7.2/Kv7.3 and Kv7.3/Kv7.4, however current research suggests that channels in the
VTA are composed of Kv7.4 homotetramers. All subtypes of Kv7 channels are slowly
activated (~100-300 ms at -30mV; (Miceli et al., 2009)), and start opening near resting
membrane potential (-60mV). M-current becomes more strongly activated at depolarized
potentials. Accordingly, M-current activation is important for repolarizing the cell, finetuning the resting membrane potential, and controlling action potential generation and
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frequency. Because Kv7 channels are slowly activated, M-current provides a stronger
inhibitory input during sustained or repetitive firing. Thus, M-current activation functions
as a brake on neuronal excitability.
M-current was named because it is blocked by muscarinic acetylcholine receptor
agonists (mAChRs) (Brown and Adams, 1980). However, Kv7 channels are inhibited by
the activation of any Gq coupled receptor (Marrion, 1997). In the last 10 years it was
established that Kv7 channels require PIP2 to enter an open state and similarly close
when PIP2 is depleted (Suh and Hille, 2007). Thus, it has become clear that
phospholipase C (PLC) hydrolysis of PIP2 into IP3 and DAG is responsible for blocking
M-current. A-kinase binding protein (AKAP79/150) directly interacts with the Kv7.2
subunit and recruits protein kinase C (PKC) where it can phosphorylate the channel
leading to inhibition of M-current (Bal et al., 2010; Hoshi et al., 2003). Kv7 channels are
also sensitive to slight increases in Ca2+ concentration (Gamper et al., 2003), and
calmodulin (CaM) interferes with the AKAP-Kv7.2 protein-protein interaction either by
prevention of the physical interaction, by blockade of PKC phosphorylation, or both (Bal
et al., 2010). Recent work as also implicated the peptide hormone ghrelin as an inhibitor
of Kv7 channels in the SNc, where it can increase the excitability of dopaminergic
neurons (Shi et al., 2013). These regulatory interactions highlight mechanisms that open
or close Kv7 channels, but not how the channels are trafficked within the neuron.
The trafficking of Kv7 channels is presently not well understood. As previously
mentioned, CaM is known to directly interact with the channel, but initial studies with
mutants lacking a CaM binding site indicated that Kv7 channels remained at the
membrane surface (Wen and Levitan, 2002). One group has suggested that the same
mutant is retained in the endoplasmic reticulum (Etxeberria et al., 2008). A recent study
showed that constitutive CaM tethering is not required for Kv7 channel function (Gomez	
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Posada et al., 2011). In short, CaM’s role in Kv7 trafficking is not well defined. In the
axon initial segment (AIS) co-assembly of the Kv7.2 and Kv7.3 subunits and interaction
with ankyrin-G are required for efficient localization (Rasmussen et al., 2007). Evidence
suggests that the protein serum-glucocorticoid-regulated kinase 1 (SGK1) increases
surface expression of Kv7 channels leading to an increase in M-current. However
whether this is due to a direct interaction of SGK1 with a Kv7 subunit or through direct
interactions with Nedd4-2 ubiquitin ligase has yet to be defined (Miranda et al., 2013;
Schuetz et al., 2008; Seebohm et al., 2005). In summary, Kv7 channel function and
trafficking are regulated through a myriad of protein-protein interactions, but exact
mechanisms are currently unclear.

Evidence for Kv7 Channels in Alcohol Use Disorders
Several recent studies have linked Kv7 channel function to drinking and other
symptoms of AUDs. Kv7 channels are linked to acute alcohol tolerance and acute
alcohol-induced memory impairments in Drosophila models (Cavaliere et al., 2012;
Cavaliere et al., 2013). Kv7 channel expression has also been more directly related to
alcohol consumption. Both alcohol self-administration and home cage drinking decrease
Kcnq3 gene transcripts in the NAc of P rats (Bell et al., 2009; Rodd et al., 2008),
suggesting a potential compensatory modulation of expression. Moreover, Metten and
colleagues (2014) reported differential expression of Kcnq2 in the ventral striatum of
mice selectively bred for high alcohol consumption/low withdrawal severity versus mice
bred for low consumption/high withdrawal severity. These authors also reported a
quantitative trait locus (QTL) on distal Chr 2, and alignment of the QTL with differential
expression data identified Kcnq2 as a candidate cis-eQTL for alcohol consumption and
withdrawal. Chromosomes 2 and 15 (locations of Kcnq2/3 have been previously linked
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to alcohol consumption as well (Drews et al., 2010). Together these data implicate a
genetic component of Kcnq genes to a drinking phenotype and a role for M-current in the
alcohol addiction process.

Statement of Problem
Pharmacological intervention is a critical component in the treatment of
individuals with AUD. Presently, few options are available to AUD patients. Novel
pharmaceuticals and targets for intervention are integral to treatment process.

Over the last several decades, it has become clear that numerous environmental and
genetic factors contribute to addiction disorders. Research indicates that some
pharmacotherapies, such as naltrexone, are more efficacious for individuals with specific
SNPs (Anton, 2008; Anton et al., 2008; Schacht et al., 2013). To better investigate the
genetic components of addiction, massive databases have been compiled and made
available to all research groups through in silico techniques. Recent evidence suggests
that Kcnq2 and Kcnq3 are associated with alcohol-related phenotypes (Bell et al., 2009;
Metten et al., 2014; Rodd et al., 2008). Therefore, the first study in this dissertation
utilized in silico approaches to identify an association of the Kcnq family of genes with
alcohol-related phenotypes. It was hypothesized that Kcnq genes occur in gene sets
accompanying alcohol phenotypes.

Several studies indicate a relationship between Kv7 channels and alcohol addiction.
Some of these include evidence that the K7 channel opener retigabine can reduce DA
release from the VTA (Hansen et al., 2008; Jensen et al., 2011; Koyama and Appel,
2006; Koyama et al., 2007; Martire et al., 2007; Sotty et al., 2009), an association of Kv7
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channels and the effects of acute alcohol on memory and tolerance (Cavaliere et al.,
2012; Cavaliere et al., 2013), and that retigabine can reduce consumption in a limited
access, forced-drinking model (Knapp et al., 2014). Altogether these studies provide
evidence that positive modulators of Kv7 channels can alter voluntary drinking in
rodents. The second study in this dissertation sought to provide clear evidence that
retigabine can reduce drinking in a model of voluntary alcohol-consumption that has high
face validity. It was hypothesized that retigabine would reduce voluntary drinking
in an alcohol-specific manner.

The addiction neurocircuitry consists of multiple brain regions that are altered during the
addiction process. In a small, but critical part of the circuitry, the ventral tegmental area
(VTA) sends dopaminergic projections to the NAc (Kalivas, 2009). Studies indicate that
there are alcohol-related adaptations in Kcnq2/3 mRNA expression in the nucleus
accumbens (NAc) in rodent models (Bell et al., 2009; Metten et al., 2014; Rodd et al.,
2008), and modulation of M-current in the VTA alters firing and DA release (Hansen et
al., 2008; Jensen et al., 2011; Martire et al., 2007; Sotty et al., 2009). These studies
suggest that Kv7 channels in both the NAc and VTA may be key regulators in alcohol
consumption. Therefore the third study in this dissertation sought to identify if Kv7
channel function in the NAc and VTA affects alcohol-drinking behaviors. It was
hypothesized that increased Kv7 channel function in the NAc and VTA would
reduce drinking.

Repeated episodes of drinking followed by withdrawal are known to induce adaptations
in the expression of select proteins throughout CNS (Becker, 1999; Breese et al., 2011;
Fadda and Rossetti, 1998). Recent genetic evidence indicates that there are alcohol	
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related adaptations in the expression of Kcnq2/3 in the NAc of rodents (Bell et al., 2009;
Metten et al., 2014; Rodd et al., 2008). We found that microinjection of retigabine to the
NAc is sufficient to reduce alcohol consumption and that alcohol-exposed rats are
sensitive to seizures induced by blocking Kv7 channels. Together these studies indicate
that Kv7 channel expression and/or function is altered in the NAc after long-term alcohol
exposure. The final experiments of this dissertation sought to characterize alcoholinduced adaptations in Kv7 channel expression in the NAc and identify a mechanism
mediating the adaptation. It was hypothesized that prolonged alcohol consumption
causes dysregulation in Kv7 channel expression and trafficking in the NAc.

In summary, the work presented in this dissertation attempts to achieve the following
goals related to the identification and characterization of a novel pharmacological
therapeutic and target for the reduction of alcohol consumption:
1. Identify Kv7 channels as a target for the reduction of alcohol drinking and
further explore the role of Kcnq genes in alcohol-related behaviors.
2. Characterize the effects of the anticonvulsant and Kv7 channel-opener
retigabine on alcohol consumption.
3. Identify regions of the addiction neurocircuitry sensitive to the effects of
retigabine on alcohol consumption.
4. Explore a biochemical basis for the pharmacological effects of retigabine in
alcohol-exposed rats.
This dissertation provides a narrative describing a complex interaction between Kv7
channels and alcohol consumption from in silico genetics to behavioral pharmacology to
alcohol-induced neuroadaptations. We identify the FDA-approved anticonvulsant
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retigabine as a potential therapeutic for the reduction of voluntary alcohol consumption.
We further provide evidence that Kv7 channels are targets for alcohol-induced plasticity,
and that membrane localization of these channels is sensitive to alcohol exposure and
withdrawal.
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CHAPTER 2: KCNQ GENES AND DRINKING PHENOTYPES
Introduction
In Chapter 1 we discussed the alarming prevalence of AUD in our society and a
decided lack of effective pharmacotherapies with minimal side effects. This is not a
simple problem as addiction disorders result from complex interactions of environmental
and genetic factors. Meta-analyses and twin studies have estimated that approximately
50% of the variance associated with drug and alcohol dependence is heritable (Agrawal
et al., 2012). Furthermore, there is evidence indicating that matching genetic variations
to specific therapeutics can improve outcomes when treating AUDs (Heilig et al., 2011;
Kranzler and McKay, 2012; Sturgess et al., 2011). Such an example is observed in
clinical studies where naltrexone is more efficacious in carriers of the A118G
polymorphism on the µ-opioid receptor gene OPRM1 (Anton, 2008; Anton et al., 2012;
Schacht et al., 2013). Therefore, identifying genetic factors that contribute to alcohol and
drug abuse is paramount to the development of new pharmacotherapies.
The Kv7 family of voltage-gated potassium channels consists of 5 subunits,
Kv7.1-Kv7.5, encoded by the genes Kcnq1-5. Four subunits come together to form the
channels responsible for M-current in peripheral organs and the brain (Jentsch, 2000;
Selyanko et al., 2002; Wang et al., 1998). Kv7.2-Kv7.5 are found abundantly in the CNS,
and emerging evidence suggests that KCNQ genes may be influenced by or influence
alcohol-related behaviors. At the genetic level, two studies have found that Kcnq3
transcriptional levels are decreased in the nucleus accumbens (NAc) following both
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alcohol self-administration and voluntary drinking paradigms in rodents (Bell et al., 2006;
Rodd et al., 2008). A recent study has associated differential expression of Kcnq2 as a
candidate cis-eQTL for alcohol consumption and withdrawal symptoms (Metten et al.,
2014). There is also evidence that KCNQ knockout drosophila are less sensitive to the
effects of alcohol compared to wildtype controls (Cavaliere et al., 2012; Cavaliere et al.,
2013). While exciting, these studies only provide a small picture of any potential
association between the KCNQ genes and alcohol consumption. We sought to further
explore this connection through in silico means.
As the –omics fields advance, researchers are able to collect vast amounts of
data with single experiments. Massive, comprehensive databases are generated and
made available to other groups through in silico approaches. We capitalized on this form
of analysis to examine the association of the Kcnq family and alcohol-related
phenotypes before pursuing behavioral approaches. The GeneWeaver software system
(GeneWeaver.org) (Baker et al., 2012) consists of a curated database of functional
genomics experimental results across 9 species and many types of experimental data
including gene expression analyses, quantitative trait locus (QTL) positional candidate
sets, curated literature annotations for gene functions, chemical interactions, and
mutation screens. Using this software system we were able to query every available
genetic study associated with an alcohol-phenotype in rodents. In this way we were able
to identify a relationship between Kcnq genes and alcohol phenotypes as well as two
compelling candidate SNPs implicating Kcnq2 with alcohol-related behaviors. These
data provide compelling preliminary evidence to suggest that matching variations in
genes to therapeutics can improve treatment outcomes in AUD patients, and that KCNQ
genes and their products are targets for treating AUD.
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Materials and Methods
GeneWeaver Bioinformatics
The GeneWeaver database was queried for ‘KcnqX alcohol’ to retrieve
experiments that implicate Kcnq2-5 in alcohol-related behaviors. Results were refined to
exclude studies in which alcohol-related behavior was not an explicit characteristic in the
experiment. Two analyses were performed: the ‘gene set graph’ to display a bi-partite
graph of genes and the studies to which they are connected, and ‘hierarchical similarity
graph’ which generates a bootstrapped graph of all populated intersections among gene
sets, arranged such that the highest order intersections are in the root or uppermost
nodes of the graph, and individual gene sets are in the leaves, or lowest level nodes in
the graph. Single nucleotide polymorphism (SNP) analyses were performed using the
Sanger Mouse Genomes Project SNP viewer (Keane et al., 2011).

Results
Integrative Functional Genomics of Kcnq Genes
The nature and extent of the relationship between the genes that encode Kv7
channels and the behavioral effects of alcohol are largely unknown, thus we performed a
GeneWeaver database search to identify previous whole genome studies in which Kcnq
genes have been associated with alcohol. Kcnq2 and Kcnq3 (Table 2.1) are differentially
expressed in a several alcohol-related experimental studies. Specifically, 12 gene sets
were found to be associated with Kcnq2 and alcohol, and 14 gene sets were associated
with Kcnq3 and alcohol. GeneWeaver analysis indicated Kcnq5 was associated with 5
gene sets, and Kcnq4 was only found in 1 alcohol-related gene set (Table 2.2).
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Table&2.1&
Table 2.1 | Gene sets associated with alcohol phenotypes containing Kcnq2/3
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Table&2.2&
Table 2.2 | Gene sets associated with alcohol phenotypes containing Kcnq4/5

Hierarchical similarity analysis indicated that Kcnq2 (Figure A.1) and Kcnq3
(Figure A.2) lie in multiple alcohol-related QTLs on mouse chromosomes (Chr) 2 and
15, respectively. In both cases, only a few other genes were also in the same multi-QTL
intersections, including Ppdpf on Chr 2 (Figure 2.1a) and Ptk2 or Adcy8 on Chr 15
(Figure 2.1b). Analysis of Kcnq5 (Figure A.3) also indicates that this gene also lies in
several alcohol-related QTLs, however, at the highest level of the hierarchy, Kcnq5 was
found with 40 other genes. Altogether, these analyses indicate that Kcnq2 and Kcnq3
are highly associated with alcohol-related phenotypes, and that while the Kcnq4 and
Kcnq5 genes are also related to these phenotypes, it is to a much lesser extent.
Because of the relatively low number of associated gene sets, subsequent analysis and
discussion will focus on Kcnq2 and Kcnq3.
Using the WTSI mouse genomes data, we performed a search for SNPs in the
region of Kcnq2 and Kcnq3 with the goal of identifying SNPs that could account for QTL
effects, which were mapped from different crosses. Therefore, we were looking for loci
that differed between C57BL/6 versus both A and DBA/2 strains. These searches
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2.1$GeneWeaver$
GeneWeaver&

yielded two compelling candidate SNPs in Kcnq2, rs27642425 (missense variant) and
rs2971971 (splice variant).

a$
a$

A

Kcnq2
Kcnq2

b$
Bb$

Kcnq3
Kcnq3

GS216898: INIA EtOH candidates
GS216898: INIA EtOH candidates
GS35071: EtOH-induced ataxia
GS35071: EtOH-induced ataxia
GS35466: EtOH-induced
GS35466:
locomotorEtOH-induced
activation
locomotor activation
GS1140: EtOH-induced
GS1140:
EtOH-induced
locomotor
activation
locomotor activation
GS135282: EtOH preference QTL, Alcp6
GS135282: EtOH preference QTL, Alcp6
GS84137: High-dose EtOH actions QTL
GS84137: High-dose EtOH actions QTL
GS84141: EtOH consumption QTL, Vacq1
GS84141: EtOH consumption QTL, Vacq1
GS3647: EtOH preference meta-analysis
GS3647: EtOH preference meta-analysis
GS84140: EtOH consumption QTL
GS84140: EtOH consumption QTL
GS135281: EtOH preference QTL, Alcp5
GS135281: EtOH preference QTL, Alcp5
GS84142: EtOH preference QTL
GS84142: EtOH preference QTL
GS84143: EtOH consumption QTL
GS84143: EtOH consumption QTL
GS75567: Chronic EtOH induced expression Amyg
GS75567: Chronic EtOH induced expression Amyg
GS37147: Chronic EtOH induced expression NAc
GS37147: Chronic EtOH induced expression NAc
GS14929: Chronic EtOH induced expression NAc
GS14929: Chronic EtOH induced expression NAc
GS115115: EtOH consumption QTL
GS115115: EtOH consumption QTL
GS84286: EtOH consumption QTL
GS84286: EtOH consumption QTL
GS115112: EtOH consumption QTL, Mec6
GS115112: EtOH consumption QTL, Mec6
GS115114: EtOH preference QTL
GS115114: EtOH preference QTL
GS135133: Reactivity NAc expression
GS135133: Reactivity NAc expression
GS84284: EtOH acceptance QTL
GS84284: EtOH acceptance QTL
GS135132: Reactivity hippocampal expression
GS135132: Reactivity hippocampal expression
GS115117: EtOH consumption QTL
GS115117: EtOH consumption QTL
GS115116: EtOH acceptance QTL, Aaq1
GS115116: EtOH acceptance QTL, Aaq1
GS115121: EtOH Lore5 QTL
GS115121: EtOH Lore5 QTL
GS135223: EtOH acceptance QTL
GS135223: EtOH acceptance QTL

Ppdpf
Ppdpf

Ptk2
Ptk2

Adcy8
Adcy8

Figure 2.1 | Gene sets containing Kcnq2 and Kcnq3 that are associated with
multiple alcohol-related phenotypes . (A) Kcnq2 was found to lie in alcohol-related
QTLs on mouse Chr 2. Ppdpf was also identified in a subset (9 of 12 gene sets) of
the multi-QTL intersections on mouse Chr 2. (B) Kcnq3 was found to lie in alcoholrelated QTLs on mouse Chr 15 in rats and mice. Ptk2 and Adcy8 in rodents were
also identified in some of the multi-QTL intersections. Phenotypes are grouped
similarity. Dark blue = motility, red = preference QTLs, purple = consumption QTLs,
orange = gene expression, light blue = acceptance QTLs, green = misc. QTLs.
Discussion
Integrative

functional

genomic

analyses

using

GeneWeaver

software

demonstrated that Kcnq2 and Kcnq3 are included in the support interval for replicated
QTLs for alcohol consumption and alcohol-related behaviors on mouse Chrs 2 and 15.
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This suggests that Kcnq2 and Kcnq3 are candidates for genetic diversity in alcoholrelated behavior found in multiple inbred mouse crosses, selected line studies, and
mutant studies. Differential expression of Kcnq2 and Kcnq3 in these populations is
indicated as a mechanism of action of the polymorphisms in the region. Our results
indicate that no other positional candidate in the intersection of the QTL loci is as highly
connected to alcohol-related phenotypes as Kcnq2 or Kcnq3.
The GeneWeaver analysis identified 3 studies investigating alcohol-associated
genetic adaptations explicitly in the NAc. The NAc is a critical region to the addiction
neurocircuitry, acting as a gateway to motor output (Kalivas, 2009). Kcnq genes are
differentially expressed in the NAc of bHR (high drug-responding) and bLR (low drugresponding) rats (Clinton et al., 2011). Two studies using RT-qPCR observed decreased
Kcnq3 mRNA expression in the NAc of P rats after alcohol consumption (Bell et al.,
2009; Rodd et al., 2008). Finally, a recent study not included in the GeneWeaver
analysis, has reported differential expression of Kcnq2 in the ventral striatum (NAc) of
mice selectively bred for high alcohol consumption/low withdrawal severity versus mice
bred for low consumption/high withdrawal severity (Metten et al., 2014). The authors
also reported a quantitative trait locus (QTL) on distal Chr 2, and alignment of the QTL
with differential expression data identified Kcnq2 as a candidate cis-eQTL for alcohol
consumption and withdrawal.	
   Together these studies suggest that KCNQ genes
specifically in the NAc are associated with alcohol phenotypes.
Several polymorphisms were identified in Kcnq2 that could account for the
genetic effects observed among the various mouse crosses, most of which involved
deviation from the C57BL/6 phenotype. The candidate SNPs identified in these
analyses, rs27642425 and rs2972972, vary between the C57BL/6 and the A and DBA/2
strains, and are not known to be clinically relevant. Alcohol consumption has not been
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extensively characterized in the A strains of mice, however there are profound
differences in the drinking patterns of C57BL/6 and DBA mice. C57BL/6 mice are an
alcohol-preferring strain whereas the DBA mice avoid alcohol. Studies indicate that
C57BL/6 mice drink more in 2-bottle choice paradigms (Meliska et al., 1995; Rhodes et
al., 2007) and short-access models (Belknap et al., 1997; Le et al., 1994), and that DBA
mice are less sensitive to alcohol-induced locomotor sensitization (Kiianmaa and
Tabakoff, 1983). Numerous recombinant inbred (RI) strains have been developed from
interbreeding the C57BL/6J and DBA/2J strains. These mice, referred to as “BXD”
strains, represent continuum of alcohol phenotypes that strongly correlate to their
genetic composition (DuBose et al., 2013; Mulligan et al., 2006; Padula et al., 2015;
Vanderlinden et al., 2013). Given these differences in alcohol phenotypes, it would be of
interest to the alcohol field to test the effects of the SNPs identified in our study on Kv7
channel currents, gene products, and alcohol-related behaviors.
Although preliminary, these data compelling pharmacogenetic evidence that
suggests that matching variations in genes to therapeutics can improve treatment
outcomes in individuals with AUDs (Anton et al., 2008; Anton et al., 2012; Kranzler and
McKay, 2012; Schacht et al., 2013). Thus, KCNQ2 and KCNQ3 and their expressed
proteins may be useful pharmacogenetic targets to treat AUDs. In the following
experiments we directly tested the role of Kv7 channels as a pharmaceutical target to
decrease alcohol consumption using the Kv7 channel opener retigabine in a home cage
drinking in a long-term access, escalation of drinking model.
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CHAPTER 3: SYSTEMIC RETIGABINE AND VOLUNTARY DRINKING
Introduction
In previous chapters we discussed the need for new pharmaceutical
interventions for treating alcohol use disorder (AUD), and the high correlation of Kcnq
genes with alcohol phenotypes across multiple rodent models of alcohol exposure. The
in silico analysis from Chapter 2 provides evidence that Kv7 channels are involved with
regulating alcohol-related behaviors and are a candidate target for treating AUD. As
such, the FDA-approved anticonvulsant and positive modulator of Kv7 channels,
retigabine may be a useful pharmacotherapy.
There is emerging evidence that Kv7 channels are a target of the actions of
alcohol on neuronal function and behavior. Acute alcohol attenuated M-current recorded
from human embryonic kidney cells expressing mammalian KCNQ2/3, ventral tegmental
area (VTA) dopamine (DA) neurons, and pyramidal neurons in hippocampus (Koyama et
al., 2007; Moore et al., 1990). Studies in Drosophila have shown that Kv7 channels
regulate acute alcohol tolerance and acute alcohol-induced memory impairments
(Cavaliere et al., 2012; Cavaliere et al., 2013). A recent study using a short-term limitedaccess (30 min) drinking paradigm showed that retigabine reduced voluntary alcohol
consumption in rats (Knapp et al., 2014). Moreover, Metten et al. (2014) recently
reported differential expression of Kcnq2 in the ventral striatum of mice selectively bred
for high alcohol consumption/low withdrawal severity versus mice bred for low
consumption/high withdrawal severity. These authors also reported a quantitative trait
locus (QTL) on distal chromosome (Chr) 2, and alignment of the QTL with differential
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expression data identified Kcnq2 as a candidate cis-eQTL for alcohol consumption and
withdrawal. Altogether these studies suggest that positive modulators of Kv7 channels
may reduce voluntary drinking in rodents.
There are multiple commonly used rodent models of alcohol consumption
(Becker, 2013; Spanagel et al., 2014), however for the purposes of this project, we
utilized the 2-bottle choice intermittent alcohol access (IAA) model in Wistar rats. The
IAA model was first introduced in the 1970s (Amit et al., 1970; Wayner and Greenberg,
1972; Wise, 1973), and simply requires that rats have intermittent 24-hour access to a
choice of water or 20% alcohol. No initiation procedure (e.g. sucrose fadeout, alcohol
vapor chamber exposure, water deprivation) is necessary to induce or maintain drinking.
Rats will escalate their daily alcohol intake over the first 6-9 drinking sessions and reach
and maintain a stable baseline of high consumption (~5-6 g/kg/24 hrs) for several
months (Simms et al., 2008; Wise, 1973). At baseline, outbred rat strains (e.g. LongEvans and Wistar) consume enough alcohol to reach pharmacologically relevant blood
ethanol concentrations (BECs) (Bell et al., 2006; Simms et al., 2008) and drink as much
as strains specifically bred to prefer drinking alcohol (e.g. P rats) (Bell et al., 2006;
Spanagel et al., 2014). This drinking model is quite versatile having been implemented in
microinjection studies (Carnicella et al., 2009), and is known to induce neuroadaptations
during the maintenance period of drinking (Bell et al., 2006; Camp et al., 2006; Hopf et
al., 2011). In summary, the IAA model induces outbred strains to consume high amounts
of alcohol without any initiation procedure and represents voluntary, choice drinking in
the rodents’ home cage.
In the experiments described in this and subsequent chapters, we used the 2bottle choice IAA paradigm to investigate the potential of retigabine as a
pharmacotherapeutic for the treatment of AUD and drinking-induced neuroadaptations in
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Kv7 channels. In the following experiments we measured the effect of systemic
retigabine on drinking behaviors and investigated the specificity of retigabine on alcohol
(ethanol; EtOH) consumption by testing its effects on tastant preference and locomotor
activity. Finally, because retigabine is known to have off-target activity at GABAA
receptors (Otto et al., 2002; Rundfeldt, 1997; Rundfeldt and Netzer, 2000), we
investigated the mechanism of action through which retigabine may reduce drinking.

Materials and Methods
Animals and Housing
Male Wistar rats (150g; P39-45) were purchased from Harlan (Indianapolis, IN)
and housed individually in standard home cages in temperature and humidity controlled
environments. In all experiments, rats were exposed to 12 hr light/dark cycles with food
and water available ad libitum during all procedures. Animals used throughout this
project were given at least 1 wk to acclimate to their respective colony rooms. All
procedures were approved by the Medical University of South Carolina Institutional
Animal Care and Use Committee and were in accordance with the NIH guidelines for the
humane care and use of laboratory animals (2011).

Two-bottle Choice 24-hr Intermittent Access & Systemic Drug Treatment
Intermittent access to alcohol (20% v/v) was performed as previously described
(Simms et al., 2008; Wise, 1973). Briefly, rats had 2 bottles of water available during
habitation, and were allowed 24 hr access to one bottle of 20% alcohol (v/v tap water)
and one bottle of tap water beginning just prior to the start of the dark cycle on Monday,
Wednesday and Friday with 24 or 48 hrs of deprivation between drinking sessions.
Placement of the alcohol solution (left or right side of the cage) was alternated between
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sessions to control for side preference. Leakage from the sipper tubes was accounted
for when weighing the bottles. Once rats reached a stable baseline alcohol consumption,
drugs were administered via intraperitoneal (IP) injections in a final volume of 3 mL/kg
30 minutes prior to alcohol availability once per week on Wednesdays following a withinsubjects design. Drug doses were as follows: 0 – 7.5 mg/kg retigabine (Axon MedChem,
The Netherlands), 0-20 mg/kg ML-213 (Tocris Bioscience, Bristol, UK), 0 – 20 mg/kg
ICA-069673 (Tocris Bioscience), and 0 – 1 mg/kg muscimol (Tocris Bioscience). Vehicle
for all drug injections was 10% Tween80 v/v saline. For combined muscimol and ICA069673 injections, drugs were made up as a single solution. Bottle weights were taken 6
and 24 hrs after alcohol availability.

Blood Ethanol Concentration
Once rats reached a stable baseline of alcohol consumption (3-4 wks), blood was
taken from the tail vein 30 min, 1 hr, and 3 hr into a drinking session. Only one time point
was collected per day with at least 1 wk between collections. Samples were collected
from multiple cohorts and the data were collapsed for analysis (n = 27 samples total).
BECs were determined using an Analox Instrument analyzer (Lunenburg, MA, USA).

Intermittent Tastant Access
Two separate cohorts of alcohol-naïve Wistar rats were placed in the 2-bottle
choice intermittent access paradigm and were given access to either 0.02% saccharin
(v/v tap water) or 15 µM quinine (Sigma-Aldrich, St. Louis, MO). Once stable
consumption was established (2-3 wks), rats were treated with IP retigabine (7.5 mg/kg)
or vehicle (10% Tween80 v/v saline) on Wednesdays using a within-subjects design.
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Locomotor Activity Assay
Two cohorts of alcohol-naïve Wistar rats were habituated to a 57 cm x 58 cm x
63 cm opaque acrylic box for 1 hr per day for 2 consecutive days. Over the next 3
consecutive days, rats received a vehicle (10% Tween80 v/v saline) or 7.5 mg/kg IP
retigabine injection 1 hr prior to a 1 hr locomotor session. Drug was administered in a
pseudo-randomized, repeated measures fashion. Activity was digitally recorded with an
overhead video camera under red light. Total movement was automatically scored using
EthoVision XT software (Noldus Information Technology, the Netherlands).

Statistical Analysis
A mixed-model analysis of variance procedure was used in the statistical
software language SAS to analyze all drinking and locomotor data using repeated

Figure$3.1$IAA$model$

measures factors. A between-within subjects method was used to determine degrees of
freedom. To follow up significant interactions and treatment effects, Fisher LSD post-hoc
tests were used. Significant correlations between BEC and alcohol consumption were
calculated using a linear regression analysis. Finally, all data are reported as mean ±
SEM and statistical significance was established with p < 0.05.
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Figure 3.1 | The intermittent alcohol access paradigm. In the IAA paradigm 20%
EtOH or tastant solution and water are made available for 24 hrs at the start of the
dark cycle on Monday, Wednesday, and Friday. Drugs were administered 30 min prior
to EtOH availability (blue arrow) on Wednesdays in a repeated measures fashion.

	
  

33	
  

A

B
0.8
0.6
0.4

5

0.2

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

0.0

Session

EtOH Consumption (g/kg)

Consumption
Preference

10

0

2.5

1.0

EtOH Preference
(ml/kg EtOH/Total ml/kg)

EtOH Consumption (g/kg)

15

2.0
1.5
1.0

R2 = 0.3741
p = 0.0007

0.5
0.0

0

10

20

30

40

50

60

70

80

90

BEC (mg/dl)

Figure 3.2 | Drinking in the IAA paradigm. (A) In the IAA model rats escalate their
drinking (red line) and preference (purple line) over the first 6 drinking sessions, after
which they maintain a stable baseline for an extended period of time. (B) EtOH
consumption (g/kg) significantly correlated with blood EtOH concentration (BEC; mg/
dL) in the first 30 – 180 min of EtOH availability.
Results
Effect of Retigabine on Voluntary Alcohol Consumption
Given the association of Kcnq genes with alcohol phenotypes and recent
evidence showing that retigabine reduces drinking a short-access model (Knapp et al.,
2014), we hypothesized that retigabine would reduce drinking in the 2-bottle choice
intermittent alcohol access drinking paradigm (Figure 3.1). In this model, rats regularly
consumed ≥3g EtOH/kg/24 hrs (range 3.01 - 11.85 g/kg/24 hrs; average 5.43 ± 0.351
g/kg/24 hrs; Figure 3.2a). Alcohol consumption (g/kg) significantly correlated with BECs
during the first 30-180 mins of a given drinking session (R2 = 0.3741, p = 0.0007; Figure
3.2b). BECs were 20.39 ± 7.504 mg/dL after 30 min of alcohol availability. After 9 wks of
drinking, rats (n = 8-14) received systemic injections of retigabine prior to alcohol
availability. Retigabine reduced alcohol consumption (Figure 3.3a) and preference
(Figure 3.3b) as indicated by significant main effects of treatment (consumption: F(3,27)
= 8.04; p = 0.0005; preference: F(3,27) = 11.21; p < 0.0001). Post-hoc analysis revealed
that 7.5 mg/kg dose reduced drinking compared to vehicle (p < 0.0001), 2.5 mg/kg
retigabine (p = 0.0055), and 5 mg/kg retigabine (p = 0.0048). 7.5 mg/kg similarly reduced
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Fig.$3.2$IP$RTG$

preference compared to vehicle (p < 0.0001), the 2.5 mg/kg dose (p = 0.0060), and the 5
mg/kg dose (p = 0.0165). There was no effect of retigabine on total liquid consumption
(F(3,25) = 1.25; p = 0.3127; Figure 3.3c).
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Figure 3.3 | Retigabine reduces voluntary drinking and alcohol preference. 7.5
mg/kg retigabine reduced (A) voluntary drinking and (B) preference. (C) Total liquid
intake were not altered by retigabine. (* p < 0.05 vs veh; φ p < 0.05 vs 2.5 mg/kg; × p
< 0.05 vs 5.0 mg/kg)
Studies investigating the ability of anticonvulsants to reduce drinking indicate that
some are effective only in high-consuming patients and high-preferring rodent lines
(Breslin et al., 2010; Chen and Holmes, 2009; Mitchell et al., 2012). Given that there are
individual differences in alcohol intake levels in Wistar rats (Blomqvist et al., 1996;
Momeni and Roman, 2014), we divided the rats into “high drinking” (HD; n = 4-7) or “low
drinking” (LD; n = 4-7) rats using a median split. At the 24 hr time point, HD rats drank
significantly more than LD rats after vehicle injections (t(12) = 4.750; p = 0.0005; mean
HD: 6.771 ± 0.7586 g/kg/24 hrs; mean LD: 2.726 ± 0.3867 g/kg/24 hrs). Systemic
retigabine had differential effects on the HD and LD groups. In HD rats, retigabine again
reduced drinking as indicated by a significant main effect of drug treatment (F(3,12) =
6.45; p = 0.0076; Figure 3.4a). Post-hoc analysis indicated that both 5.0 and 7.5 mg/kg
retigabine significantly reduced drinking compared to vehicle (p = 0.0012 and p =
0.0239, respectively). We also observed a main effect of treatment on alcohol
preference (F(3,12) = 3.20; p = 0.0421; Figure 3.3d). Post-hoc analysis showed that 7.5
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mg/kg retigabine reduces preference compared to vehicle (p = 0.0134). Retigabine had
no effect on total liquid intake in HD rats (F(3,10) = 1.60; p = 0.2498; Figure 3.4c).
In the LD group of rats, there was a significant interaction of treatment and time
on alcohol consumption (F(3,12) = 4.21; p = 0.0300; Figure 3.4d). At the 6 and 24 hr
time points, 7.5 mg/kg retigabine reduced drinking (post-hoc: p = 0.0499 and p = 0.0177,
respectively). Interestingly, 5.0 mg/kg retigabine increased alcohol consumption
compared to vehicle at 24 hrs (p = 0.0008). There was a main effect of treatment
(F(3,12) = 9.30, p = 0.0019) on alcohol preference, indicating that 7.5 mg/kg retigabine
reduced preference in LD rats (p = 0.0002; Figure 3.4e). Total fluid consumption was
not affected by retigabine (F(3,12) = 2.59; p = 0.1012; Figure 3.4f). Together these data
indicate that systemic retigabine can reduce drinking in some populations of rats and
that the effect is dependent on dose and the individual’s propensity to drink.
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3.3$IP$RTG$HD$vs$LD$
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Figure 3.4 | Systemic retigabine differentially affects consumption in high and
low drinking populations of rats. Drinking rats were divided into two groups defined
by the median level of EtOH consumption. (A) In HD rats, 5.0 and 7.5 mg/kg
retigabine reduced EtOH consumption. (B) 7.5 mg/kg retigabine also reduced EtOH
preference. There was not a significant effect of retigabine on (C) total fluid intake in
high drinking rats. In LD rats (D) 7.5 mg/kg retigabine again reduced drinking 6 and
24 hrs after EtOH availability. 5.0 mg/kg increased EtOH consumption at the 24 hr
time point. (E) 7.5 mg/kg reduced preference, and there was no effect of retigabine
on (F) total fluid consumption. (* p < 0.05 vs veh; φ p < 0.05 vs 2.5 mg/kg; × p < 0.05
vs 5.0 mg/kg; + p < 0.05 vs 7.5 mg/kg)
Effect of Retigabine on Motility and Taste Perception
It is possible that the effect of retigabine on drinking is due to non-alcohol related
behaviors such as taste perception and motility. To investigate the effect of systemic
retigabine on taste preference, alcohol-naïve rats (n = 8) were given access to either
0.02% saccharin or 15 µM quinine in the IAA model. In these experiments, retigabine
(7.5 mg/kg) did not significantly alter consumption of saccharin (F(1,6) = 0.18; p =
0.6828; Figure 3.5a). However, retigabine did increase consumption of the aversive	
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tasting quinine (main effect of treatment: F(1,6) = 0.636; p = 0.0451; Figure 3.5a). We
again divided the rats into HD and LD groups based on median tastant intake. There
was no significant difference in drinking between HD and LD rats in the saccharin cohort
(t(6) = 2.264; p = 0.0642; n = 4) or in the quinine cohort (t(5) = 1.917; p = 0.1143; n = 34; data not shown), suggesting these cohorts cannot be segregated. In addition, this

3.4$Home$cage$behaviors$
analysis would be underpowered to make strong conclusions. Subsequent discussion

will consider the saccharin and quinine cohorts as single populations of drinkers.
Together, these data indicate that retigabine does not simply decrease intake of all
drinking solutions, but rather that the reduction appears specific for alcohol.
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Retigabine has also been shown to decrease locomotor activity (Hansen et al.,
2007), raising the possibility that this drug reduces drinking through motor impairments.
To address this, alcohol-naïve rats (n = 8) received systemic retigabine (7.5 mg/kg) or
vehicle prior to a 60 min open field exploration task. We found no effect of retigabine on
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lateral movement when activity was binned in 10 min periods (F(1,7) = 4.35; p = 0.0756;
Figure 3.5b). There was also no effect of retigabine on cumulative locomotor activity
across the entire 60 min test period (t(7) = 0.1850; p = 0.8585; Figure 3.5c). These
experiments indicate that retigabine reduces voluntary drinking in an alcohol-specific
manner.

Determining the mechanism of action of retigabine
Retigabine is a relatively non-selective Kv7 channel positive modulator and
increases M-current in homo- and heterotetrameric channels (EC50

= 0.6-6.2 µM)

(Gunthorpe et al., 2012). Furthermore at high enough concentrations (> 10 µM) (Otto et
al., 2002; Rundfeldt, 1997; Rundfeldt and Netzer, 2000), retigabine can activate GABAA
receptors. To determine a mechanism through which retigabine reduces drinking we
administered Kv7 channel-specific and subunit-selective drugs to rats in the IAA

3.5$ML213$

paradigm (Brueggemann et al., 2014; Yu et al., 2010). First we administered 20 mg/kg
ML-213, a Kv7.2/Kv7.4-selective positive modulator to IAA rats (n = 10-11). As shown in
Figure 3.6, ML-213 had no effect on alcohol consumption (F(1,9) = 2.14; p = 0.1774),
preference (F(1,9) = 0.99; p = 0.3469), or total liquid intake (F(1,9) = 2.01; p = 0.1901).
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Figure 3.6 | ML-213 does not affect alcohol consumption. Rats in the IAA
paradigm received 20 mg/kg IP injections of the Kv7.2/Kv7.4 channel-selective
positive modulator ML-213 and drinking was measured 6 and 24 hrs after EtOH
availability. In the total population of rats, ML-213 had no affect on (A) EtOH
consumption, (B) preference, or (C) total liquid intake.
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We again divided the cohort into HD (n = 5) and LD (n = 5-6) groups, where HD
rats consumed more alcohol than LD rats (t(9) = 3.378, p = 0.0082; mean HD: 4.716 ±
0.4605 g/kg/24 hrs; mean LD: 2.591 ± 0.427 g/kg/24 hrs). In the HD group, ML-213
reduced voluntary alcohol consumption (F(1,4) = 14.39; p = 0.0192; Figure 3.7a) and
preference (F(1,4) = 11.63; p = 0.0270; Figure 3.7b) as indicated by significant main

3.6$ML213$SPLIT$

effects of treatment. There was no effect of ML-213 on total liquid intake (F(1,4) = 2.71; p
= 0.1751; Figure 3.7c). In LD rats there was no effect of ML-213 on alcohol consumption
(F(1,4) = 0.69; p = 0.4539; Figure 3.7d), preference (F(1,4) = 1.31; p = 0.3155; Figure
3.7e), or total fluid intake (F(1,4) = 0.37; p = 0.5770; Figure 3.7f). Together these data
suggest that Kv7.2 and Kv7.4 are important for the regulation of drinking behaviors in
HD rats.
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Figure 3.7 | ML-213 decreases voluntary alcohol consumption in HD rats. Rats
in the IAA paradigm received 20 mg/kg IP injections of the Kv7.2/Kv7.4 channelselective positive modulator ML-213. In HD rats ML-213 reduced alcohol (A)
consumption and (B) preference and had no effect on (C) total fluid intake. In LD rats
there was no effect of ML-213 on alcohol (D) consumption, (E) preference, or (F) total
liquid intake. (* p < 0.05 vs vehicle)
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Next we administered the Kv7.2/Kv7.3-selective positive modulator ICA-069673

3.7$ICA$

to IAA rats (n = 10-15). As shown in Figure 3.8, 20 mg/kg of ICA-069673 was unable to
reduce alcohol consumption (F(3,57) = 1.027; p = 0.3877), preference (F(3,56) = 0.6152;
p = 0.6080), or total fluid intake (F(3,57) = 2.407; p = 0.0765).
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Figure 3.8 | ICA-069673 does not affect voluntary alcohol consumption. Rats in
the IAA paradigm received IP injections of the Kv7 channel-specific agonist
ICA-069673 (ICA) and drinking was measured 6 and 24 hrs after EtOH availability. In
the total population of rats, ICA-069673 had no affect on (A) EtOH consumption, (B)
preference, or (C) total liquid intake.

We divided the cohort into HD (n = 4-8) and LD (n = 5-7) rats, where HD rats
drank significantly more than the LD group (t(12) = 3.307; p = 0.0063; mean HD: 5.158 ±
0.823 g/kg/24 hrs; mean LD: 2.218 ± 0.3353 g/kg/24 hrs). There was no effect of ICA069673 in the HD group on alcohol consumption (F(1,3) = 2.23; p = 0.2321; Figure
3.9a), preference (F(1,3) = 3.39; p = 0.1627; Figure 3.9b), or total liquid intake (F(1,3) =
2.46; p = 0.2150; Figure 3.9c). Similarly, in the LD group, there was no effect of the ICA
compound on consumption (F(1,3) = 4.73; p = 0.1180; Figure 3.9d), preference (F(1,3)
= 3.31; p = 0.1665; Figure 3.9e), or total fluid intake (F(1,3) = 2.35; p = 0.2520; Figure
3.9f. Due to the lack of effect of ICA-069673 on the total population of rats and when
divided into HD and LD groups, subsequent experiments and discussion will consider
cohorts treated with ICA-069673 as a whole.
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Figure 3.9 | ICA-069673 does not affect voluntary alcohol consumption in HD
and LD rats. Rats in the IAA paradigm received IP injections of the Kv7 channelspecific agonist ICA-069673 (ICA). In HD rats, ICA-069673 had no affect on (A) EtOH
consumption, (B) preference, or (C) total liquid intake. The ICA compound also had
no affect on these parameters when measured in LD rats (D, E, F).
In a separate cohort of rats, we tested the ability of ICA-069673 (20 mg/kg) and
muscimol (1 mg/kg), a GABAA-specific agonist, administered both separately and
concurrently to reduce drinking. This dose of muscimol was selected because a previous
report showed that 3 mg/kg of systemic muscimol reduced alcohol intake in an operant
self-administration paradigm, however, a 1 mg/kg dose had no effect (Janak and
Michael Gill, 2003). Individually, the ICA compound (20 mg/kg) and muscimol (1 mg/kg)
did not alter drinking compared to vehicle (Figure 3.10a). As indicated by a main effect
of treatment (F(3,18) = 4.96; p = 0.0110), the combined injection of ICA-069673 with
muscimol reduced drinking compared to vehicle (p = 0.0059). There was a main effect of
treatment on alcohol preference (F(3,18) = 9.46; p = 0.0006; Figure 3.10b), and posthoc analysis revealed that the combined injection of the ICA compound and muscimol
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resulted in decreased preference for alcohol compared to vehicle (p = 0.0009).
Individually, ICA-069673 and muscimol did not reduce alcohol preference compared to
vehicle. Finally, there was no treatment effect on total fluid consumption (F(3,18) = 0.52;

3.9$ICA$+$MUSC$

p = 0.6767; Figure 3.10c). Taken together these data indicate opening Kv7.2/Kv7.3containing channels may be insufficient to alter drinking behaviors on their own but may
work synergistically with GABAA receptors to reduce alcohol consumption.
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Figure 3.10 | Co-administration of muscimol and ICA-069673 reduce voluntary
drinking. Rats in the IAA paradigm received injections of 20 mg/kg ICA-069673 (ICA)
and 1 mg/kg muscimol (Mus) both separately and concurrently. Joint injection of Mus
and ICA decreased (A) EtOH consumption and (B) preference. There was no effect
of the drugs individually on drinking. There was also no effect of any treatment on (C)
total liquid intake. (* p < 0.05 compared to veh, Φ p < 0.05 compared to Mus, × p <
0.05 compared to ICA)
Discussion
In these studies we showed that systemically administered retigabine, a Kv7
channel positive modulator, reduces voluntary alcohol consumption in the IAA model.
Analysis of individual drinking indicates that retigabine has differential effects on high
and low drinking populations of rats. Furthermore, retigabine did not decrease saccharin
or quinine consumption alcohol-naïve rats, and there was no effect of retigabine on
motility. Collectively these experiments suggest that retigabine may be a useful
treatment for AUD, and that Kv7 channels play a role in alcohol consumption.
A key finding from these experiments is that positive modulation of Kv7 channels
decreased voluntary intake and preference using a rodent model of long-term, 24 hr
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intermittent alcohol consumption without saccharin fadeout (Simms et al., 2008; Wise,
1973). Our findings are in agreement with a study which found retigabine to reduce
drinking in a short-access (30 min) saccharin-induced drinking model (Knapp et al.,
2014). In our model, 7.5 mg/kg retigabine reduced consumption by approximately 50%
without altering total fluid intake. Using the same IAA rodent model to compare 2 FDAapproved drugs for treating AUDs (naltrexone and acamprosate), the high dose of
retigabine was at least equally as effective at reducing drinking. Naltrexone and
acamprosate reduced intake by approximately 30% and 10-50% at the 6 hr and 24 hr
time points, respectively (Li et al., 2010; Sabino et al., 2013; Simms et al., 2008).
Similar to inconsistent findings reported in clinical and preclinical studies testing
anticonvulsants (Padula et al., 2013), we also observed bidirectional effects of retigabine
on drinking that were dependent on level of intake and dose. When administered
systemically, the two doses of retigabine (5 and 7.5 mg/kg) decreased intake in the HD
rats. In the LD rats, the high dose decreased drinking whereas the intermediate dose
increased drinking. Although there was no influence on saccharin consumption, we did
find that retigabine increased quinine consumption, suggesting that this drug either
enhances or antagonizes bitter taste perception. In turn, because alcohol has a bitter
taste component (Scinska et al., 2000) and there is a genetic contribution to taste
perception in mice (Blizard, 2007), alterations in gustatory processes could be a
mechanism to explain increased alcohol consumption at moderate doses of retigabine
by LD rats. Interestingly, others have reported similar dissociations between the
amounts of alcohol consumed and anticonvulsant effects. In non-treatment seeking
alcohol abusers, the anticonvulsant levetiracetam increased consumption in selfreported moderate drinkers (Mitchell et al., 2012). In C57BL/6J mice, administration of
25 mg/kg topiramate increased alcohol preference while 50 mg/kg topiramate reduced
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alcohol preference (Gabriel and Cunningham, 2005). In rats, topiramate is efficacious at
reducing drinking in alcohol-preferring strains (Breslin et al., 2010; Zalewska-Kaszubska
et al., 2013) but fails to reduce drinking in strains not specifically bred for high alcohol
preference (Breslin et al., 2010). Together, these studies indicate that while retigabine is
able to reduce alcohol consumption, its efficacy may be dependent on individual
differences and an underlying genetic disposition to drink.
The mechanism through which systemic retigabine reduces alcohol consumption
is not immediately clear. Unlike most other anticonvulsants, altering Kv7 channel
function can influence DA transmission in mesencephalic/VTA DA neurons (Hansen et
al., 2008; Koyama and Appel, 2006; Sotty et al., 2009), and Kv7 channel positive
modulators can attenuate evoked DA efflux and synthesis in the striatum (Hansen et al.,
2006; Jensen et al., 2011; Martire et al., 2007; Sotty et al., 2009). Studies investigating
differences between strains bred to prefer and avoid alcohol indicate that compared to
the avoiding strains, alcohol preferring animals have decreased levels of dopamine
receptor 2 (Drd2) mRNA expression in the NAc (Bice et al., 2011; Imperato and Di
Chiara, 1986; Yim and Gonzales, 2000), decreased basal levels of DA in the NAc
(Gongwer et al., 1989; Murphy et al., 1987; Stefanini et al., 1992; Zhou et al., 1995), and
a greater DA response to an acute alcohol challenge (Bustamante et al., 2008).
Together, these studies indicate that rodents bred for high alcohol consumption have
decreased dopaminergic tone in the NAc and an increased dopaminergic response to
alcohol challenge compared to their low alcohol-preferring counterparts. Chronic alcohol
treatment sensitized VTA DA neurons to alcohol-induced excitation (Brodie, 2002) and
enhanced NAc neuron firing after chronic alcohol exposure facilitated alcohol seeking
after a period of abstinence (Hopf et al., 2007). Given that retigabine can decrease firing
of VTA dopaminergic cells (Koyama and Appel, 2006), it is possible that retigabine
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reduces drinking by restoring aberrant dopaminergic tone in high drinking rats.
Subsequent studies further investigate role of Kv7 channels in the NAc and VTA.
Although established as a Kv7 channel opener, it not highly selective for specific
subunits (Kv7.2/7.3 EC50 = 1.6 µM; Kv7.4 EC50 = 5.2 µM), and some studies suggest
that at high concentrations in vitro (10-50 µM), retigabine can increase activity at GABAA
receptors (Otto et al., 2002; Rundfeldt, 1997; Rundfeldt and Netzer, 2000). Here we
showed that the Kv7.2/Kv7.4-selective modulator ML-213 reduced voluntary drinking in
HD rats, however there was no effect of the Kv7.2/Kv7.3-selevtive positive modulator
ICA-069673. Together this suggests that the Kv7.2 and Kv7.4 subunits are particularly
important for regulating drinking behaviors. In addition, because Kv7.4 is almost
exclusively found in midbrain DA neurons (Hansen et al., 2008), this data indicates that
Kv7 channels in the VTA are involved in the regulation of drinking behaviors.
Evidence suggests that systemically increasing GABA function can influence
operant responding for alcohol. IP injection of the GABAA agonist muscimol decreases
self-administration (Janak and Michael Gill, 2003). Similarly, IP gamma-vinyl GABA (a
GABA transaminase inhibitor) dose-dependently decreases alcohol consumption,
suggesting that increased GABA concentration in the CNS leads to decreased drinking
(Wegelius et al., 1993). These studies suggest that the ability of retigabine to reduce
drinking in the IAA model might be mediated through combined action at Kv7 channels
and GABAA receptors. Here we showed that separate administration of the Kv7 channelspecific positive modulator, ICA-069673 (Amato et al., 2011), and muscimol, a GABAA
receptor agonist did not reduce alcohol consumption in the IAA model. In contrast, a
simultaneous injection of the ICA compound and muscimol reduced both alcohol
consumption and preference. This data would indicate that systemic retigabine reduces
drinking through its activity at both Kv7 channels and GABAA receptors; however, there
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are caveats to this conclusion. 20 mg/kg IP doses of retigabine in mice result in a brain
concentration of 2.7898 µM (Zhou et al., 2015). It is therefore unlikely that a 7.5 mg/kg IP
injection of retigabine in rats yields the > 10 µM brain concentration required to result in
off-target activity at GABAA receptors in the CNS. In addition, the Kv7 channel-specific
positive modulator, ML-213, reduced drinking in HD rats, indicating that modulation of
Kv7 channels is sufficient to reduce alcohol consumption. Together these data suggest
that the ability of the combined muscimol and ICA injection to reduce alcohol
consumption recapitulates the effect of retigabine on drinking, but not necessarily the
mechanism. The additive effect of muscimol and the ICA compound does suggest that
Kv7 channel positive modulators, including retigabine, may be useful as an adjunct
therapy with other anticonvulsants such as the GABA analogues (i.e. gabapentin and
vigabatrin) discussed in Chapter 1. While further investigation of this possibility would be
interesting, it is outside the scope of this project. Subsequent studies in this dissertation
investigate alcohol consumption and the function of Kv7 channels by way of retigabine
microinjected into nodes of the addiction neurocircuitry.
In summary, these studies indicate that systemic administration of retigabine can
reduce alcohol consumption in a rodent model of voluntary drinking in an alcohol-specific
manner. Given that a recent study has shown retigabine to be well tolerated in moderate
alcohol drinkers when co-administered with an intoxicating dose of alcohol (Crean and
Tompson, 2013), retigabine may be useful as a pharmacotherapy for treating AUD.
However, care should be taken clinically to insure that the dose is sufficient as to not
increase the desire to drink in some patients. These studies further implicate Kv7
channels in drinking-related behaviors. Subsequent experiments will investigate the
effect of retigabine in regions of the addiction neurocircuitry on alcohol consumption.
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CHAPTER 4: MICROINFUSION OF RETIGABINE IN THE ADDICTION NEUROCIRCUITRY AND
VOLUNTARY DRINKING
Introduction
Studies from this project and previous reports indicate that systemic
administration of the Kv7 channel positive modulator, retigabine, reduces voluntary
alcohol consumption (Knapp et al., 2014). These results indicate not only that retigabine
may be a suitable treatment for alcohol use disorder (AUD), but also that Kv7 channels
may play a role in the addictive behaviors. Although the addiction neurocircuitry
incorporates nearly the entire brain, certain regions are at the core of the addiction
process. It would therefore be interesting to identify specific portions of the circuitry in
which activation of Kv7 channels mediates a reduction in voluntary drinking.
The central portion of the addiction neurocircuitry includes the prefrontal cortex
(PFC), nucleus accumbens (NAc), the ventral pallidum (VP), and the ventral tegmental
area (VTA) (Koob and Volkow, 2010)). These regions are also at the core of any
behavior learned in response to salient environmental stimuli (Kalivas, 2002). Both
aversive and rewarding (salient) stimuli increase the synaptic release of dopamine (DA)
from the VTA onto neurons in every node of corticomesolimbic circuit (Berridge and
Robinson, 1998). The PFC and other regions intimately associated with learning and
memory (e.g. the hippocampus) send glutamatergic projections to the NAc. The NAc
integrates its glutamatergic, dopaminergic, and limbic inputs to initiate an adaptive
response through reciprocal GABAergic connections with the VP and downstream motor
circuitry (Kalivas, 2002). Over repeated exposure to the same or similar stimuli, the DA
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response stabilizes, and the habitual motor circuitry becomes primarily responsible for
behavioral output.
Acute exposure to drugs of abuse and alcohol induce a greater release of DA
compared to naturally rewarding stimuli (Kalivas, 2009; Kuczenski and Segal, 1999;
Marshall et al., 1997). Numerous studies have shown that acute and chronic alcohol
exposure stimulates the activation of mesolimbic DA (Brodie, 2002; McBride and Li,
1998; Yoshimoto et al., 2003), inducing a 25-50% increase in DA in the NAc over
baseline (Weiss et al., 1996). The dopaminergic response elicited by chronic exposure
to drugs of abuse and alcohol results in the formation of strong, salient memories of the
drug in question. As a consequence, the individual becomes motivated by the perceived
importance of drugs or alcohol, leading to addicted behaviors. Rodent models of chronic
alcohol exposure indicate that during withdrawal, the activity of VTA neurons is
suppressed, resulting in decreased DA in the NAc (Bailey et al., 1998; Shen, 2003). The
NAc can be subdivided into two primary regions: the core and the shell. The NAc shell is
primarily associated with drug reward (Rodd-Henricks et al., 2002; Sellings and Clarke,
2003), whereas the core contributes to the initiation of motivated and conditioned
behaviors (Cornish and Kalivas, 2000; McFarland et al., 2003). From this perspective,
dopaminergic projections from the VTA to the NAc are critical to the learning and
initiation of addictive behaviors.
In the following experiments we investigated a role for Kv7 channel function in
the NAc core and VTA in drinking behaviors. Here we microinfused retigabine to these
regions of rats drinking in the intermittent alcohol access (IAA) paradigm and measured
alcohol consumption. Similar to Chapter 3, retigabine reduced alcohol consumption with
individual differences in drinking patterns. This study indicates that Kv7 channel
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activation in key regions of the addiction neurocircuitry is sufficient to reduce alcohol
consumption in high drinking populations of rats.

Materials and Methods
Animals and Housing
Male Wistar rats (150g; P39-45) were purchased from Harlan (Indianapolis, IN)
and housed individually in standard home cages in temperature and humidity controlled
environments with a 12 hr light/dark cycle (lights out: 1000 hr). Food and water were
available ad libitum throughout the study. All procedures were approved by the Medical
University of South Carolina Institutional Animal Care and Use Committee and were in
accordance with NIH guidelines for the humane care and use of laboratory animals
(2011).

Two-bottle Choice Drinking
Intermittent access to alcohol (20% v/v) was performed as previously described
in Chapter 3 (Simms et al., 2008; Wise, 1973). Briefly, rats had 2 bottles of water
available during habitation, and were allowed 24 hr access to one bottle of 20% alcohol
(v/v tap water) and one bottle of tap water beginning just prior to the start of the dark
cycle on Monday, Wednesday and Friday. Placement of the alcohol solution (left or right
side of the cage) was alternated between sessions to control for side preference.
Leakage from the sipper tubes was accounted for when weighing the bottles.

Cannula Implantation and Microinjections
After reaching a stable baseline of alcohol consumption in the IAA drinking
paradigm (2-3 wks), separate cohorts of rats were anesthetized with vaporized
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isoflurane and placed in a stereotaxic instrument (David Kopf Instruments Tujunga, CA).
For NAc microinjections, bilateral microinjection guide cannula (26 ga O.D.; PlasticsOne
Roanoke, VA) were aimed to terminate 1 mm dorsal to the NAc core following previously
established coordinates (anterior-posterior +1.18 mm, medial-lateral ± 1.2 mm, dorsalventral -5 mm) (Gass et al., 2011). For VTA microinjections, bilateral cannula were
aimed to terminate 2 mm dorsal to the region following previously established
coordinates (anterior-posterior -5.6 mm, medial-lateral ± 2.1 mm, dorsal-ventral -7.1,
10°) (Mahler et al., 2013). The guide cannulas were secured to the skull with stainless
steel screws and dental cement (OrthoJet; Lang Dental Manufacturing Co., Inc). 33 ga
removable obturators were used to limit the obstruction of the guides by tissue and
contamination from external debris. We used topical 2% xylocaine and 2% triple
antibiotic ointments to treat the wound and suture it closed. All rats were given carprofen
(2.5 mg/kg, SC) for post-operative pain management for 4 consecutive days following
the surgery.
Rats received microinjections in their home cages beginning 30 min prior to
alcohol availability. 33 ga injectors were connected to two Hamilton syringes mounted to
a pump (Harvard Apparatus, 11 Plus, Holliston, MA) set to deliver fluids at a rate of 0.5
µl/min. Injectors were inserted bilaterally to a depth of 1-2 mm beyond the tip of the
guide cannula. Retigabine (2.5 - 10 ng in 0.01% DMSO v/v saline) or vehicle (0.01%
DMSO v/v saline) was delivered in a final volume of 0.5 µl/side. After the infusion, the
injectors were left in the guides for 1 min to allow drug diffusion. Rats were given at least
15 min to rest in their home cages prior to alcohol availability. Drinking was measured at
3, 6, and 24 hrs. Microinjections were completed as a pseudo-random within-subjects
design (NAc: n = 13, 4-6 microinjections each; VTA: n = 12, 6 microinjections each).
Upon completion of the experiment, rats were euthanized and the brains were Nissl
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stained for cannula placement. Rats with cannulas that missed the NAc core (6 total) or
VTA (no misses) were excluded from analysis for that brain region.

Statistical Analysis
A mixed-model analysis of variance procedure was used in the statistical
software language SAS to analyze all drinking data using repeated measures factors. A
between-within method was used to calculate degrees of freedom. Fisher LSD post-hoc
tests were used to follow up significant interactions and treatment effects. Finally, all
data are reported as mean ± SEM and statistical significance was established with p <
0.05.

Results
Effect of Retigabine in the NAc Core on Voluntary Drinking
Evidence indicates that the NAc core regulates alcohol-seeking behaviors
(Abrahao et al., 2013; Hopf et al., 2010; Seif et al., 2013), and recent studies suggest
that Kcnq gene expression is altered in this region after alcohol exposure (Bell et al.,
2009; Metten et al., 2014; Rodd et al., 2008). To investigate the role of Kv7 channels in
the NAc, we infused retigabine to this region (Figure 4.1a) and measured alcohol
consumption in the IAA paradigm (n = 13). Intra-accumbal retigabine had no effect on
alcohol consumption (F(2,24) = 2.59, p = 0.0962; Figure 4.1b), preference (F(2,24) =
2.70, p = 0. 0.0877; Figure 4.1c), or total fluid consumption (F(2,24) = 0.36; p = 0.7018;
Figure 4.1d).
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Figure 4.1 | Retigabine in the NAc does not reduce drinking in the total
population of rats. (A) Representative images of the placement of bilateral guide
cannula targeting the NAc core. Grey circles indicate placements for individual rats.
Microinfusion of 5 and 10 ng of retigabine did not affect (B) EtOH consumption, (C)
preference, or (D) total liquid intake.
In Chapter 3 we discussed individual differences in the Wistar strain associated
with drinking (Blomqvist et al., 1996; Momeni and Roman, 2014), and found that
systemic retigabine had differential effects on alcohol consumption that were dependent
on the individual’s propensity to drink. We again divided the cohort into HD and LD
populations based on the median value of alcohol consumption. HD rats (n = 5-6) drank
significantly more than LD rats (n = 7) at baseline (t(11) = 3.385; p = 0.0061; mean HD:
5.963 ± 0.7906 g/kg/24 hrs; mean LD: 2.871 ± 0.5095 g/kg/24 hrs). In HD rats there was
a main effect of retigabine on drinking (F(2,10) = 6.39; p = 0.0163; Figure 4.2a) and
preference (F(2,10) = 7.81; p = 0.0091; Figure 4.2b). Post-hoc analysis revealed that 10
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ng of retigabine reduced consumption (p = 0.0054) and preference (p = 0.0027)
compared to vehicle. There was no effect of treatment on total liquid consumption
(F(2,10) = 0.07; p = 0.9352; Figure 4.2c). In LD rats there was no effect of retigabine on
alcohol consumption (F(2,12) = 2.41; p = 0.1317; Figure 4.2d), preference (F(2,12) =

4.2$NAc:$MI$RTG$HD$vs$LD$
1.87; p = 0.1957; Figure 4.2e), or total liquid consumption (F(2,12) = 0.75; p = 0.4939;
Figure 4.2f). Together these data suggest that Kv7 channels in the NAc core are
involved with regulating alcohol intake in HD rats.
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Figure 4.2 | Retigabine in the NAc reduces alcohol consumption in HD rats.
Rats were divided into high and low drinking groups based on the median value of
EtOH consumption. In the HD population, 10 ng of retigabine reduced (A) EtOH
consumption and (B) preference. There was no effect on (C) total fluid intake. In LD
rats, retigabine had no effect on (D) EtOH consumption, (E) preference, or (F) total
fluid intake. (* p < 0.05 vs veh)
Effect of Retigabine in the VTA on Voluntary Drinking
DA release from the VTA is a central aspect of the addiction process (Koob and
Le Moal, 2005), and M-current and retigabine affect DA signaling. Retigabine can
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decrease firing of DA VTA neurons (Koyama and Appel, 2006). Altering Kv7 cannel
function can also influence DA transmission in mesencephalic/VTA DA neurons (Hansen
et al., 2007; Koyama and Appel, 2006; Sotty et al., 2009), and Kv7 channel positive
modulators can attenuate evoked DA efflux and synthesis in the striatum (Hansen et al.,
2006; Jensen and Yaari, 1997; Martire et al., 2007; Sotty et al., 2009). Thus Kv7
channels in the VTA may regulate drinking behaviors. In IAA drinking rats (n = 11-12),

4.3$VTA:$MI$RTG$

we bilaterally implanted guide cannulas to target the VTA (Figure 4.3a). In the total
population of drinking rats, retigabine had no effect on alcohol consumption (F(2,20) =
0.23, p = 0.8001; Figure 4.3b), preference (F(2,20) = 0.29, p = 0.7546; Figure 4.3c), or
total fluid consumption (F(2,20) = 3.15, p = 0.0649; Figure 4.3d).
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Figure 4.3 | Retigabine in the VTA does not reduce drinking in the total
population of rats. (A) Representative images of the placement of bilateral guide
cannula targeting the VTA. Grey circles indicate placements for individual rats.
Microinfusion of 5 and 10 ng of retigabine did not affect (B) EtOH consumption, (C)
preference, or (D) total liquid intake.
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We again grouped the rats into HD and LD populations based on median alcohol
consumption. As expected, HD rats (n = 5-6) consumed more alcohol than LD rats (n =
5-6) at baseline (t(9) = 4.379; p = 0.0018; mean HD: 6.787 ± 0.7439 g/kg/24 hrs; mean
LD: 2.568 ± 0.5560 g/kg/24 hrs). In the HD group, there was an interaction of time and
alcohol consumption (F(4,20) = 3.04; p = 0.0412; Figure 4.4a). Post-hoc analysis
indicates that both 5 ng (p = 0.0004) and 10 ng (p = 0.0030) of retigabine reduced
drinking at the 24 hr time point. As evidenced by a main effect of treatment (F(2,10) =
5.21; p = 0.0282), retigabine also reduced alcohol preference (Figure 4.4b). Post-hoc
analysis indicates that the 5 ng (p = 0.0122) and 10 ng (p = 0.0328) dose of retigabine
reduced preference compared to vehicle. Finally, intra-VTA retigabine decreased total
fluid intake (F(2,10) = 9.59, p = 0.0047; Figure 4.4c). Again, 5 ng (p = 0.0024) and 10 ng
(p = 0.0057) retigabine reduced intake compared to vehicle. In LD rats (n = 5-6), there
was no effect of retigabine on alcohol consumption (F(2,8) = 2.72, p = 0.1255; Figure
4.4d). However, retigabine increased alcohol preference (F(2,8) = 4.86, p = 0.0416;
Figure 4.4e) and total fluid intake (F(2,8) = 5.59, p = 0.0303; Figure 4.4f). Post-hoc
analysis revealed that 5 ng of retigabine increased alcohol preference compared to
vehicle (p = 0.0143). 5 ng (p = 0.0248) and 10 ng (p = 0.0164) also reduced total liquid
intake compared to vehicle. These data indicate that Kv7 channel function in the VTA
play a role in the regulation of drinking behaviors, although the effect may not be specific
to alcohol.

	
  

56	
  

4.4$VTA:$MI$RTG$HD$vs$LD$
High Drinking

8

B

Veh
5 ng
10 ng

6

*

4
2
0

3 hr

6 hr

*

0.8

*
φ

0.6
0.4

*
φ

*
φ

0.2
0.0

24 hr

C

1.0

3 hr

6 hr

Total Liquid Intake (ml/kg)

10

EtOH Preference
(ml/kg EtOH/Total ml/kg)

EtOH Consumption (g/kg)

A

150

100

*×
50

0

24 hr

*×

*×
3 hr

6 hr

24 hr

Low Drinking

8

E

Veh
5 ng
10 ng

6
4
2
0

3 hr

6 hr

24 hr

F

1.0
0.8
0.6

*

*

*

0.4
0.2
0.0

3 hr

6 hr

24 hr

Total Liquid Intake (ml/kg)

10

EtOH Preference
(ml/kg EtOH/Total ml/kg)

EtOH Consumption (g/kg)

D

150

100

*
φ

50

*
φ
0

3 hr

*
φ

6 hr

24 hr

Figure 4.4 | Retigabine in the VTA reduces alcohol consumption HD rats. Rats
were divided into high and low drinking groups based on the median value of EtOH
consumption. In the HD population, 5 and10 ng of retigabine reduced (A) EtOH
consumption at the 24 hr time point. (B) EtOH preference was reduced by 5 ng
retigabine. Finally, (C) 10 ng retigabine reduced total fluid intake at 6 and 24 hrs. In
LD rats, retigabine had no effect on (D) EtOH consumption or (F) total fluid intake. 5
ng of retigabine increased (E) preference in LD rats. (* p < 0.05 vs veh; φ p < 0.05 vs
10 ng; × p < 0.05 vs 5 ng)
Effect of Retigabine in Missed Cannula Placements
Given the nature of the coordinates used to target the NAc, 5 of the 6 missed
cannula placements terminated in the lateral ventricle (Figure 4.5a), effectively resulting
in an intracranial ventricle (ICV) microinjection. These rats drank more than the average
median level of alcohol consumption across the other cohorts (> 4.47 g/kg/24 hrs).
Retigabine significantly reduced alcohol consumption (F(2,8) = 12.09; p = 0.0038;
Figure 4.5b), preference (F(2,8) = 12.42; p = 0.0035; Figure 4.5c), and total liquid
intake (F(2,8) = 10.30; p = 0.0061; Figure 4.5d) as indicated by significant main effects
of treatment. Post-hoc analysis indicated that both 5.0 and 10 ng of retigabine reduced
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alcohol consumption (p = 0.0020, p = 0.0041), preference (p = 0.0028, p = 0.0024), and

4.5$ICV$RTG$

liquid intake (p = 0.0076, p = 0.0026). These data indicate that ICV retigabine reduces
voluntary alcohol consumption, but that it is it partially mediated through a reduction in
total liquid intake.
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Figure 4.5 | Effect of retigabine in the lateral ventricle. 5 or the 6 missed cannula
placements from the NAc microinjection study terminated in the (A) lateral ventricle,
effectively resulting in an ICV microinjection. 5.0 and 10 ng of retigabine reduced (B)
EtOH consumption, (C) preference, and (D) total liquid intake. (* p < 0.05 vs veh)
Discussion
In these experiments we showed that microinfusion of retigabine to the NAc core
or the VTA, key nodes of the addiction neurocircuitry, is sufficient to reduce voluntary
alcohol consumption in the IAA paradigm. Similar to the findings from Chapter 3, we
observed individual differences in the efficacy of microinjected retigabine: the drug was
only able to reduce alcohol intake and preference in the high drinking population of rats.
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Together these studies suggest that Kv7 channels in the VTA and NAc help regulate
alcohol-drinking behaviors.
The key finding from this set of experiments is that microinfusion of retigabine to
the NAc core and VTA of high drinking rats reduces voluntary drinking and alcohol
preference. Retigabine may accomplish this through the restoration of aberrant DA tone
found in high drinking rats. Kv7 channel function can influence DA transmission in
mesencephalic/VTA DA neurons (Hansen et al., 2008; Koyama and Appel, 2006; Sotty
et al., 2009) and Kv7 channel positive modulators can attenuate evoked DA efflux and
synthesis in the striatum (Hansen et al., 2006; Jensen et al., 2011; Martire et al., 2007;
Sotty et al., 2009). Decreased levels of dopamine receptor 2 (Drd2) mRNA expression
are reported in the NAc of high-alcohol preferring mice compared to low-alcohol
preferring mice (Bice et al., 2011; Imperato and Di Chiara, 1986; Yim and Gonzales,
2000). Microdialysis studies indicate that high-alcohol drinking (HAD) rats have a lower
baseline of DA in the ventral striatum (NAc) compared to low-alcohol drinking (LAD) rats
(Gongwer et al., 1989; Murphy et al., 1987; Stefanini et al., 1992; Zhou et al., 1995).
Finally alcohol-naïve University of Chile Bibulous rats (derived from Wistar rats) have a
greater DA response in the NAc to an acute alcohol challenge compared to abstainer
rats (Bustamante et al., 2008). Together these studies indicate that alcohol preferring
rats have decreased dopaminergic tone in the NAc, and an increased dopaminergic
response to alcohol exposure compared to their low alcohol-preferring counterparts.
Thus, intra-accumbal and intra-VTA retigabine could be acting to restore abnormal DA
tone in animals predisposed to consume higher amounts of alcohol.
Alternatively, retigabine may reduce consumption through attenuating an alcoholinduced increase in excitability. Studies indicate that chronic alcohol treatment sensitizes
VTA DA neurons to alcohol-induced excitation (Brodie, 2002). Also, burst firing in the
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VTA encodes the salience of a given environmental stimuli or drug (Overton and Clark,
1997), and alcohol withdrawal increases the probability of burst firing in VTA neurons
(Hopf et al., 2007). Furthermore, Kv7 channel positive modulators can prevent burst
firing of VTA neurons (Sotty et al., 2009). Given that microinfusion of retigabine to VTA
reduced alcohol consumption in HD rats, it is possible that retigabine reduces drinking
by suppressing VTA activity. In addition, electrophysiology studies indicate that spike
firing is increased in the NAc 3-5 weeks after prolonged alcohol self-administration (Hopf
et al., 2010), and that medium spiny neurons (MSNs) in the NAc display increased miniexcitatory postsynaptic currents and increased paired pulse ratios during withdrawal
from prolonged alcohol exposure (Marty and Spigelman, 2012a; Spiga et al., 2014).
Together these data suggest that the NAc is more excitable during withdrawal. In
addition, Kv7 channel activation can prevent presynaptic release of DA in the NAc
(Martire et al., 2007). Furthermore, inhibition of the NAc core inhibits the reinstatement of
cocaine seeking (Stefanik and Kalivas, 2013), and alcohol self-administration (Hodge et
al., 1997). Given that M-current activation is important for repolarizing the cell, finetuning the resting membrane potential, and controlling action potential generation and
frequency (Miceli et al., 2009), and retigabine potently reduces firing frequency (DalbyBrown et al., 2006; Tatulian et al., 2001; Wickenden et al., 2000), it is possible that intraaccumbal core retigabine reduces voluntary alcohol consumption through a reduction in
NAc core firing and subsequent initiation of drinking behaviors.
In Chapter 3 we showed that a moderate and high dose of IP retigabine reduced
alcohol consumption in HD rats, whereas the moderate dose increased consumption in
LD rats. Here, we show that intra-accumbal retigabine had no effect on drinking in LD
rats, suggesting that Kv7 channels in the NAc are not responsible for the increased
drinking caused by moderate systemic doses of retigabine in LD rats. In contrast,
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microinfusion of retigabine to the VTA increased alcohol preference in LD rats, and there
was a trend towards increased alcohol consumption. This suggests that increased Mcurrent in the VTA mediates the increase in drinking caused by retigabine in LD rats.
Given that retigabine alters DA release from the VTA to the NAc (Hansen et al., 2006;
Jensen et al., 2011; Martire et al., 2007; Sotty et al., 2009), and the decreased release of
DA in response to alcohol observed in alcohol avoiding rat (Bustamante et al., 2008), it
is possible that in low drinking rats, retigabine in the VTA alters the rewarding perception
of alcohol.
Altogether these studies suggest that retigabine could act through several
mechanisms in the NAc and VTA to affect drinking. Specifically, retigabine likely reduces
activity in the NAc core, which prevents the initiation of alcohol drinking. Retigabine
could also regulate aberrant DA release from the VTA to the NAc to alcohol, preventing
its rewarding effects and subsequent consumption. Although outside the scope of this
project, additional investigation into the interaction of retigabine, dopamine, and alcohol
is necessary and will be an area of focus in future studies.
In these experiments there was not a significant interaction of time and treatment
on alcohol consumption when retigabine was infused to the NAc. However, visual
inspection of the graphed values suggests that intra-accumbal retigabine does not begin
to affect drinking until 6 hrs after presentation of alcohol. Given the instant availability of
drug to bind receptors when microinfused, we predicted an immediate effect of
retigabine on drinking. The delay in the effect may be contributed to multiple
mechanisms. At 3 hrs into a drinking session, rats receiving vehicle infusions drink
between 1.5 and 2 g/kg alcohol. Any variability in drinking between rats would prevent
an effect of retigabine at such low intake. Another possible explanation for a lack of
effect at 3 hrs is that the dopaminergic response to alcohol presentation and drinking in
	
  

61	
  

the IAA model is slow. We argue that retigabine decreases alcohol consumption by
stabilizing an aberrant DA response to alcohol. In most rat models of drinking, DA
release is measured after an IP injection of an intoxicating amount of alcohol (Feduccia
et al., 2014; Soderpalm et al., 2000; Steensland et al., 2012). Operant self-administration
procedures with rats suggest a 10-20 min delay in peak DA release during short (30-60
min) sessions where ~2 g/kg of alcohol is consumed (Melendez et al., 2002; Weiss et
al., 1993). One study investigating DA release in a choice continuous access model for
6% alcohol, found a 60 min delay in peak DA release (Ericson et al., 1998). How this
and an operant self-administration paradigm correlate to our IAA home cage drinking is
unclear. It would of great interest to use microdialysis techniques to measure DA release
in the NAc during a drinking session in our model.
In the HD population of rats, 5 and 10 ng of retigabine in the VTA reduced
voluntary alcohol consumption at the 24 hr time point. However, alcohol preference did
not correlate with consumption. 5 ng of retigabine reduced preference at the 3 and 24 hr
time points. Retigabine also reduced total fluid consumption 6 and 24 hrs after alcohol
availability. Clearly, these data are difficult to interpret; however disruption in naturally
rewarding stimuli has been observed after modifying acetylcholine in the VTA.
Cholinergic agonists infused to the VTA have been shown to reduce alcohol
consumption and increase saccharin consumption in limited access models of drinking
(Katner et al., 1997). Microinfusion of atropine, a metabotropic acetylcholine (mACh)
receptor antagonist, to the VTA decreases food intake (Rada et al., 2000). Atropine can
also prevent the reduction of M current by the mACh receptor agonist muscarine
(Pfaffinger, 1988). Therefore in our studies, retigabine may be modifying the behavioral
response to the potentially naturally rewarding perception of water. Although outside the
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scope of this project, it would be interesting to investigate the role of VTA Kv7 channels
in water and saccharin/sucrose consumption in both naïve and alcohol-exposed rats.
The missed placements from the NAc microinjection study provided an
opportunity to examine the effect of what were effectively ICV infusions of retigabine on
alcohol consumption in HD rats. We found that 5 and 10 ng of retigabine reduced
alcohol consumption and preference. These data are in agreement with ours and others’
studies showing that systemic retigabine reduces drinking (Knapp et al., 2014).
Interestingly, we observed a decrease in total fluid intake, suggesting that the effect of
retigabine administered directly to the CNS is not alcohol-specific.
At high concentrations (> 10 µM), retigabine is known to have off target effects at
GABAA receptors (Rundfeldt and Netzer, 2000). It is possible that the reduction in
drinking when retigabine is microinfused into the NAc and VTA is mediated, in part,
through GABAergic mechanisms. Here we microinfused a 5 – 10 ng of retigabine in a
total volume of 0.5 µL, which corresponds to a concentration of 32.97 – 65.94 µM. This
would be sufficient to activate GABAA receptors in vitro, however the drug is likely to
rapidly diffuse throughout a volume of brain tissue greater than 0.5 µL, reducing the
effective concentration. Furthermore, 100 µM retigabine does not alter the amplitude of
GABAA receptor responses in patch clamp recordings from rat entorhinal cortex (Hetka
et al., 1999), suggesting a minimal effect of retigabine on GABA signaling. Together, this
suggests that the reductions in alcohol consumption by retigabine in the NAc and VTA
are likely not mediated by GABAergic mechanisms.
In summary, these studies indicate that retigabine differentially affects voluntary
alcohol consumption in high and low drinking populations of outbred rats. Specifically,
we showed that microinfusion of retigabine to the NAc core and VTA is sufficient to
reduce alcohol consumption in high drinking rats with no effect in low drinking animals.
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This suggests that Kv7 channels in key regions of the addiction neurocircuitry play a
critical role in drinking behaviors in HD rats. Subsequent experiments will investigate
alcohol-induced adaptations in Kv7 channels, which may underlie the effects of
retigabine on drinking.
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CHAPTER 5: DRINKING-INDUCED NEUROADAPTATIONS OF KV7 CHANNELS
Introduction
Studies from the previous chapters indicate that Kcnq genes are associated with
alcohol phenotypes and that positive modulation of Kv7 channels reduces voluntary
alcohol consumption both systemically and when microinjected into the nucleus
accumbens (NAc) core or ventral tegmental area (VTA). The ability of retigabine to
reduce drinking could be the result of an augmented baseline function of Kv7 channels
or a stabilization of an alcohol-induced adaptation in Kv7 channel physiology. The crucial
nature of the NAc to addictive behaviors (Kalivas, 2009; Russo et al., 2010) and
evidence indicating a high level of alcohol-induced plasticity of excitatory mechanisms
and Kcnq genes in the NAc, strongly suggest that Kv7 channels undergo adaptations
after prolonged alcohol consumption.
In Chapter 4, we discussed the brain regions associated with addiction as a
circuit encompassing the prefrontal cortex (PFC), NAc, VTA, and ventral pallidum (VP)
(Kalivas, 2002; Koob and Volkow, 2010). The traditional focus of addiction research has
been the VTA and its dopaminergic projections, however in the past several decades,
there has been a shift to focus on the corticostriatal circuitry in which DA terminals from
the VTA are embedded (Kalivas, 2009). These regions are responsible for generating
learned and habitual behaviors, and for dictating how an individual responds to
environmental stimuli. The circuitry is composed of limbic regions including the NAc,
PFC, amygdala, and VTA; and a motor subcircuit including the motor cortex, dorsal
striatum, and the substantia nigra. In a simplified interpretation of the corticostriatal
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circuit, the NAc acts as a gateway through which information processed in the limbic
circuit gains access to the motor circuit (Groenewegen et al., 1996; Yin and Knowlton,
2006). Over time repeated behaviors (such as taking drugs of abuse) reduce the
involvement of the limbic regions, and the motor circuitry is more heavily relied upon until
a novel stimulus reengages the limbic circuitry (Barnes et al., 2005; Doya, 2008; Yin and
Knowlton, 2006). Many drugs of abuse, including alcohol, hijack this circuit reducing the
glutamatergic input from the PFC to the NAc, resulting in behaviors mediated by the
habitual motor circuitry (Kalivas, 2009). This view of addictive behaviors marks the NAc
as a key region of the addiction neurocircuitry for therapeutic intervention.
The NAc is well-researched in alcohol addiction, and studies indicate that
prolonged alcohol exposure leads to aberrant glutamate signaling (Gass and Olive,
2008; Griffin et al., 2014; Neasta et al., 2010; Neasta et al., 2011) and altered glutamate
receptor expression in the NAc (Cozzoli et al., 2009; Neasta et al., 2011; Obara et al.,
2009; Szumlinski et al., 2008; Zhou et al., 2007). Previous research has shown that
medium spiny neurons (MSNs) in the NAc become hyperexcitable after chronic alcohol
exposure (Marty and Spigelman, 2012a, b; Padula et al., 2015; Spiga et al., 2014).
Furthermore, a recent rodent proteomics study found over 50 proteins whose expression
was altered in the NAc by alcohol exposure (Uys et al., 2015). Thus, the NAc is a region
not only critical to the addition neurocircuitry, but also highly susceptible to alcoholinduced adaptations.
Studies highlighted in the GeneWeaver analysis discussed in Chapter 2 provide
genetic evidence that Kv7 channel expression may be altered in the NAc by alcohol
exposure. Two studies using RT-qPCR found that Kcnq3 mRNA expression in the NAc
of P rats was decreased after alcohol consumption (Bell et al., 2009; Rodd et al., 2008).
Also, Kcnq genes are differentially expressed in the NAc bHR (high drug-responding)
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and bLR (low drug-responding) rats (Clinton et al., 2011). Finally a recent study has
reported differential expression of Kcnq2 in the ventral striatum (NAc) of mice selectively
bred for high alcohol consumption/low withdrawal severity versus mice bred for low
consumption/high withdrawal severity (Metten et al., 2014). The authors also reported a
quantitative trait locus (QTL) on distal Chr 2, and alignment of the QTL with differential
expression data identified Kcnq2 as a candidate cis-eQTL for alcohol consumption and
withdrawal. These studies indicate that prolonged alcohol consumption leads to
adaptations of Kv7 channels in the NAc.
In the following experiments we systemically administered the selective Kv7
channel antagonist XE-991 to long term drinking rats in the IAA model. We observed
that blocking these channels induced convulsive activity, suggesting that drinking in the
IAA model induces adaptations in the Kv7 channel expression and/or function. We then
investigated IAA-induced adaptations in the expression patterns of the Kv7 channel
subunit Kv7.2 in the NAc. The Kv7.2 subunit selected for analysis because it has been
extensively studied in medium spiny neurons (MSNs) and is a key target for Kv7 channel
regulation (Cooper et al., 2001; Delmas and Brown, 2005; Hansen et al., 2008; Martire
et al., 2007; Shen et al., 2005). We observed that the expression of Kv7.2 in specific
membrane microdomains is altered by alcohol withdrawal. Given that a recent study
suggesting that hyper-SUMOylation of Kv7 channels decreases M-current (Qi et al.,
2014), we examined SUMOylation as a possible post translation modification that could
mediate these expression patterns.
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Materials and Methods
Animals and Housing
Male Wistar rats (150g; P39-45) were purchased from Harlan (Indianapolis, IN)
and housed individually in standard home cages in temperature and humidity controlled
environments with a 12 hr light/dark cycle (lights out: 1000 hr). Food and water were
available ad libitum throughout the study. All procedures were approved by the Medical
University of South Carolina Institutional Animal Care and Use Committee and were in
accordance with NIH guidelines for the humane care and use of laboratory animals
(2011).

Two-bottle Choice Drinking
Intermittent access to alcohol (20% v/v) was performed as previously described
in Chapters 3 and 4 (Simms et al., 2008; Wise, 1973). Briefly, rats had 2 bottles of water
available during a 1 wk habitation period. Rats were allowed 24 hr access to one bottle
of 20% alcohol (v/v tap water) and one bottle of tap water beginning just prior to the start
of the dark cycle on Monday, Wednesday and Friday with 24 or 48 hrs of deprivation
between drinking sessions. Placement of the alcohol solution (left or right side of the
cage) was alternated between sessions to control for side preference. Leakage from the
bottles was accounted for when weighing the bottles.

XE-991 Sensitivity
While conducting the initial systemic retigabine studies described in Chapter 3,
we tried to prevent the effects of retigabine on drinking with pretreatment of the selective
Kv7 channel antagonist XE-991. However, XE-991 induced convulsive behaviors (e.g.,
wild jumping behavior) in all rats within 10 min of the injection and the study was
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terminated. This was surprising given that the dose used (2 mg/kg) has been shown to
be innocuous and even improve cognitive function (Fontan-Lozano et al., 2011).
Although the outcome of this experiment was unexpected, it suggested that prolonged
drinking in the IAA model alters Kv7 channel function and/or expression. To formally
measure XE-991-induced convulsant activity, Wistar rats that had been drinking for 12
wks in the IAA model received XE-991 (2 mg/kg; IP in sterile saline, 3 ml/kg; Tocris
Bioscience; Ellisville, MO) or vehicle (saline) immediately prior to their dark cycle and
returned to their home cage. Behavior was digitally recorded under red light for 20 min.
A blinded observer manually scored behavioral abnormalities on a modified Rancine
seizure scale (Luttjohann et al., 2009). Briefly, this scale uses 10 behavioral categories
to assess seizure occurrence and intensity (from relatively least to most severe: MS =
motionless staring, FJ = facial jerks, NJ = neck jerks, CS = clonic seizures while sitting,
CLB = clonic seizures while lying on its belly, TCLB = tonic–clonic seizures while lying
on its belly, T = tonic seizure, CLS = clonic seizures while lying on its side, TCLS =
tonic–clonic seizures lying on its side, WJ = wild jumping).

Subcellular Fractionation and Western Blot Analysis
Bilateral tissue punches were taken targeting the NAc core from alcohol-naïve
and long-term drinking rats (at least 12 wks of alcohol consumption) 72 hr after the last
session. Detergent resistant membrane (DRM) and detergent soluble membrane (DSM)
fractions were prepared using Triton X-100 (Mulholland et al., 2011). Briefly, a Dounce
homogenate was prepared and centrifuged at 23,000 x g for 30 min. The supernatant or
‘intracellular’ (IC) fraction that contains cytosolic proteins and intracellular light
membranes (ILMs) was separated and the pellet was resuspended with buffer
containing 0.5% Triton X-100. The suspension was rotated for 15 min at 4¹C and then
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centrifuged at 12,000 x g for 20 min, generating the soluble (DSM) and insoluble (DRM)
fractions. Western blots were performed on these fractions following previous methods
(McGuier et al., 2014). Membranes were stained for total protein concentration with
amido black, and blots were normalized to the total protein stain (Aldridge et al., 2008).
Kv7.2 antibody was purchased from Alomone Labs (#APC-050; Jerusalem, Israel).
AKAP150 antibody was purchased from EMD Millipore (#07-210; Billerica, MA). The
SGK1 antibody (#S5188) and naphthol blue black were purchased from Sigma-Aldrich.

SUMOylation Assay
To identify possible SUMOylation modification sites on Kv7.2 channels, we
performed a bioinformatics search using SUMOplotTM with accession numbers O43526
and O88543 for human and rat Kv7.2, respectively. The SUMOylation assay was
completed using the VIVAbind SUMO kit (VIVA Bioscience, Exeter, UK) following the
manufacturer’s instructions. Briefly, tissue was collected targeting the NAc core of rats
and then subfractioned to generate DRM and DSM fractions using the methods
described above. The protein concentrations of each DRM and DSM sample were
determined using a Bradford assay kit (Pierce Scientific, Rockford, IL). Equal amounts of
protein from each sample were rotated with 40 µL of the SUMO matrix overnight at 4°C.
SUMOylated proteins were eluted at 95°C in 45 µL of 14% SDS (v/v PBS). An equal
volume of each eluate was run on a polyacrylamide gel for western blot analysis as
described above, and Kv7.2 (Alomone Labs, Jerusalem, Israel) was used for the
detection of SUMOylated proteins. To characterize differences in Kv7.2 SUMOylated
between fractions, tissue was collected from adult, male, alcohol-naïve Wistar rats.
Tissue to quantify alcohol-induced differences in Kv7.2 SUMOylation was collected from
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alcohol-naïve and IAA-exposed (at least 12 wks of alcohol consumption), male, rats after
72 hr withdrawal from alcohol in the IAA paradigm.

Statistical Analysis
Due to the non-Gaussian distribution of the behavioral responses in the XE-991
sensitivity study, non-parametric statistical analyses including a Chi-square test for trend
and a Mann Whitney test were performed. Western blot data was analyzed using twotailed t-tests to compare samples from naïve and IAA rats. Finally, all data are reported
as mean ± SEM and statistical significance was established with p < 0.05.

Results
Sensitivity to XE-991 After Long-term Drinking
As an alternative approached to determining the role of Kv7 channels in alcohol
drinking we treated IAA rats with an innocuous dose of the selective Kv7 channel blocker
XE-991 in combination with retigabine, hypothesizing that this would block the effects of
retigabine on consumption and increase drinking. To test this, we systemically
administered 2 mg/kg XE-991 or vehicle 15 min prior to treatment with 7.5 mg/kg
retigabine or vehicle. However, in our initial experiment with XE-991, treatment of longterm drinking rats rapidly induced convulsive behaviors (e.g., wild jumping behavior) in
all rats within 10 min of administration and the study was discontinued. This finding
suggested that rats with a history of long-term alcohol consumption were sensitive to the
proconvulsant effects of Kv7 channel blockade. We tested this hypothesis by
administering XE-991 (2 mg/kg) or vehicle to a different cohort of alcohol-naïve and
long-term drinking rats (n = 4-5/group) immediately prior to a normal drinking session
such that the rats were 24 hrs withdrawn from alcohol. Vehicle injections did not produce
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any seizure-like activity in naïve or alcohol exposed rats (data not shown). XE-991
administration significantly increased the percentage of IAA rats that experienced more
severe seizure activity compared to alcohol-naïve controls (χ2 for trend (1, n = 9) =

5.1$XE991$SensiVvity$

4.908, p = 0.0267; Figure 5.1a). Rats with a 12-wk history of drinking also displayed a
significant increase in the severity of the worst convulsive activity score compared to
naïve rats that were treated with XE-991 (U = 2.000, p = 0.0238; Figure 5.1b), indicating
that long-term drinking alters Kv7 channel function.
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Figure 5.1 | Rats with a history of drinking were more sensitive to Kv7 channel
blockade-induced seizures. (A) More rats with a history of alcohol consumption
showed enhanced convulsive activity in response to XE-991 (2 mg/kg) compared
with alcohol naïve controls (in order of increasing severity MS = motionless staring,
FJ = facial jerks, NJ = neck jerks, CS = clonic seizures while sitting, CLB = clonic
seizures while lying on its belly, TCLB = tonic–clonic seizures while lying on its belly,
T = tonic seizure, CLS = clonic seizures while lying on its side, TCLS = tonic–clonic
seizures lying on its side, WJ = wild jumping). (B) XE-991 treatment significantly
increased the severity of seizure-like activity in long-term drinking rats compared to
naïve rats (e.g. wild jumping vs motionless staring). (* p < 0.05 compared to naïve)
Alcohol-Induced Adaptations in Kv7.2 Expression
The results from the GeneWeaver analysis and microinjection study indicate that
Kv7 channels in the NAc play a role in alcohol drinking. These data, combined with IAA
rats being more sensitive to Kv7 blockade compared to naïve rats, suggest that Kv7
channel expression and/or function in the NAc may be altered due to long-term drinking
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in the IAA model. Tissue punches targeting the NAc core were obtained after 72-hr
withdrawal from the last drinking session. Samples from control and IAA rats (n = 56/group) were fractionated into detergent resistant membrane (DRM), detergent soluble
membrane (DSM), and intracellular (IC) fractions. Figure 5.2a shows the relative
expression levels of Kv7.2, AKAP150, and SGK1 in these subfractions. Consistent with
previous reports, Kv7.2 was expressed in all 3 fractions, AKAP150 was primarily
expressed in the DRM fraction, and SGK was primarily expressed in the IC fraction
(Delmas and Brown, 2005; Garcia-Martinez and Alessi, 2008; Hoshi et al., 2003).
Western blot analysis indicated that Kv7.2 expression was significantly increased in
DRMs in IAA rats compared to naïve rats (t(10) = 2.250; p = 0.0482; Figure 5.2b),
whereas Kv7.2 expression was decreased in the DSMs of IAA rats compared to naïve
controls (t(10) = 7.237; p < 0.0001). Figure 5.3 depicts a cartoon of these expression
patterns. There was no effect of alcohol drinking on Kv7.2 channel expression in the IC

5.2$Kv7.2$Traﬃcking$

fraction (t(9) = 0.425; p = 0.6812). 72 hr withdrawal did not alter expression levels of
AKAP150 (t(10) = 0.3578; p = 0.7279) or SGK1 (t(9) = 0.5282; p = 0.6101; Figure
5.2c,d).
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Figure 5.2 | Excessive drinking and abstinence altered surface trafficking of
Kv7.2 channels in the NAc. (A) Representative blots showing relative expression
patterns of Kv7.2, AKAP150, and SGK1 in detergent resistant membrane (DRM),
intracellular (IC), and detergent resistant membrane (DSM) fractions. (B) Kv7.2
channel expression is altered in the DRM and DSM fractions after long-term drinking
and 72 hr abstinence. A history of drinking did not affect (C) AKAP150 or (D) SGK1
expression levels. (* p < 0.05 compared to naïve)
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Figure 5.3 | Illustration of
the alcohol-induced
trafficking pattern of Kv7
channels. (Top) Alcoholnaïve rats have an equal
distribution of Kv7.2containing channels in
detergent resistant
membrane (DRM; blue
background) as detergent
soluble membrane (DSM;
green background).
(Bottom) During EtOH
withdrawal, expression of
Kv7.2-containing channels
decreases in the DSM and
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Alcohol-Induced SUMOylation Pattern of Kv7.2 Channels
Post-translational modifications (PTMs) of proteins can influence their subcellular
expression patterns (Perkins, 2006; Reed et al., 2006). SUMOylation is one such PTM
that results in the covalent attachment of a small ubiquitin-like modifier (SUMO) protein
that has recently been linked to multiple forms of synaptic plasticity and protein function
(Luo et al., 2013). A recent report indicated that hyper-SUMOylation of Kv7 channels
reduces M-current, suggesting that SUMOylation is be a key regulator of Kv7 channel
function (Qi et al., 2014). A search for SUMOylation tetrapartite motifs (Ψ-K-x-D/E;
where Ψ is a hydrophobic residue, K is an acceptor lysine, x is any amino acid, and D/E
are acidic residues) revealed 12 possible SUMOylation modification sites on human and
rat Kv7.2, 3 of which were identified as high probability motifs (human: K21, K625, and
K662; rat: K21, K608, and K645). In rat Kv7.2, three consensus motifs were identified on
the N-terminus (K21, K49, K66), 1 was cytosolic between transmembrane segments S2
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Fig.&5.4&SUMOyla>on&Sites&
and S3 (K166), 1 was extracellular between S5 and the pore (K255), 1 was in the poreforming intramembrane (K283), and six were located on the C-terminus (Figure 5.4).

Figure 5.4 | Potential
SUMOylation sites on the Cterminus of Kv7.2. A search of
the rat Kv7.2 peptide for the
SUMOylation consensus
sequence ((Ψ-K-x-D/E; where
Ψ is a hydrophobic residue, K
is an acceptor lysine, x is any
amino acid, and D/E are acidic
residues) revealed 6 potential
sites (orange circles with
arrows) on the C-terminus. Two
of these sites fall within the
CaM and AKAP binding
regions.
Using a commercially available kit, we first characterized SUMOylated Kv7.2
protein levels in the NAc of alcohol-naïve rats (n = 4). We observed no difference in the
expression of SUMOylated Kv7.2 in the DRM and DSM of the NAc (t(4) = 1.202, p =
0.2955; Figure 5.5a). We then performed a SUMOylation assay on fractionated tissue
collected from the NAc of control and IAA rats (n = 6/group). The expression of
SUMOylated Kv7.2 in the DSM fraction was significantly decreased in IAA rats
compared to naïve rats (t(9) = 2.427; p = 0.0382; Figure 5.5b). There was no difference
in SUMOylated Kv7.2 expression in the DRM fraction (t(10) = 0.9774; p = 0.3514).
Finally, the ratio of SUMOylated Kv7.2 to total Kv7.2 was significantly decreased in the
DRM after IAA (t(8) = 3.395; p = 0.0094; Figure 5.5c), but not in the DSM (t(8) = 1.260;
p = 0.2431) Combined, these data indicate that long-term alcohol drinking modifies
Kv7.2 channel trafficking and SUMOylation levels between DRM and DSM fractions.
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Figure 5.5 | Alcohol withdrawal alters the SUMOylation state of Kv7.2 in the
NAc. (A) SUMOylated Kv7.2 is equally expressed in the detergent resistant
membrane (DRM) as it is in the detergent soluble membrane (DSM) fractions in the
NAc. (B) Expression of SUMOylated Kv7.2 in the DSM is decreased in the the NAc of
IAA rats compared to alcohol-naïve controls, but not in the DRM. (C) The ratio of
SUMOylated Kv7.2 to total Kv7.2 was significantly decreased in the DRM after IAA
but not in the DSM (* p < 0.05 vs naive).
Discussion
Retigabine, a Kv7 channel positive modulator, is able to reduce voluntary alcohol
consumption when systemically administered and when microinfused into the NAc core
of HD rats in the IAA model. Here we show that long term drinking rats in the IAA
paradigm are more sensitive to seizures induced by Kv7 blockade, indicating that
prolonged alcohol consumption alters the expression and/or function of Kv7 channels in
the CNS. Biochemical assays indicate that drinking and withdrawal alter the surface
trafficking of the Kv7.2 subunit within the plasma membrane. Furthermore, this
adaptation is associated with alcohol-induced plasticity in SUMOylation state of Kv7.2.
Altogether these studies provide the first evidence that prolonged intermittent drinking
and withdrawal induce adaptations in Kv7 channels that are likely mediated by changes
in SUMOylation of the channel.
A major finding in these studies is that rats with a long history of intermittent
alcohol consumption were more sensitive to spontaneous seizures induced by systemic
administration of a selective Kv7 channel blocker. Mutations in the Kcnq2 gene that
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cause benign familial neonatal convulsions, type 1 produce a decrease in M-current
(Maljevic et al., 2008). Mice expressing mutations in Kv7.2 channels display reduced Mcurrent, decreased threshold for pentylenetetrazole (PTZ)-induced seizures, and
hypersensitivity to the pro-convulsant effects of Kv7 channel blockade (Kapfhamer et al.,
2010; Otto et al., 2009; Otto et al., 2006; Otto et al., 2004; Watanabe et al., 2000). In
contrast, the SGK1.1 transgenic mice with enhanced M-current display diminished
sensitivity to kainic acid-induced seizures (Miranda et al., 2013). The dose of XE-991
that produced wild jumping behavior and spontaneous clonic seizures in our long-term
alcohol drinking rats has not been reported to cause adverse behaviors in alcohol-naïve
rats and mice (Korsgaard et al., 2005; Sander et al., 2012; Xu et al., 2010), though one
study reported cognitive enhancing effects in mice at a higher dose than we tested
(Fontan-Lozano et al., 2011). While chronic alcohol exposure is known to produce
neuroadaptations that alter sensitivity to proconvulsant drugs, this is not a global, nonspecific phenomenon (Becker et al., 1998; Finn and Crabbe, 1999; Stephens et al.,
2001).

M-current

is

thought

to

regulate

intrinsic

excitability

and

counter

afterdepolarizations and sustained NMDA receptor activation required to trigger burst
firing in the hippocampus (Gu et al., 2005; Qiu et al., 2007; Yue and Yaari, 2006). Burst
firing in CA1 neurons can synchronize population activity and drive seizure initiation
(Jensen and Yaari, 1997). Moreover, while the distribution of Kv7.2 channels is
widespread, this subunit is concentrated in specific subsets of neurons responsible for
controlling neural network oscillations and rhythmic brain activity (Cooper et al., 2001;
Leao et al., 2009). Thus, the hypersensitivity to XE-991 suggests that expression or
function of Kv7 channels may be decreased by repeated periods of intoxication and
withdrawal in brain regions that control motor output and seizure generation, such as the
basal ganglia circuitry or hippocampus.
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We directly investigated alcohol-induced adaptations in the Kv7.2 subunit and
observed that long-term consumption and abstinence produces microdomain-dependent
neuroadaptations in Kv7.2 channels in the NAc. The most common pairing of Kv7
channel subunits in the CNS is Kv7.2/Kv7.3 (Delmas and Brown, 2005), and studies
indicate that most of the modifications and protein interactions that influence Kv7
channel trafficking and function occur at or on the C-terminus of the Kv7.2 subunit (Bal
et al., 2010; Hoshi et al., 2003; Suh and Hille, 2007). Evidence suggests that Kv7.2
channels are expressed in multiple subcellular compartments in neurons, having been
reported to localize to the axon initial segment (AIS), lipid rafts, nodes of Ranvier,
somatodendritic domains of GABAergic output neurons, dendritic spines, and
presynaptic terminals of tyrosine hydroxylase positive axonal projections (Arnsten et al.,
2010; Cooper et al., 2000; Devaux et al., 2004; Pan et al., 2006; Roche et al., 2002).
Some plasma membrane proteins found in the AIS, lipid rafts, and dendritic spines are
insoluble in Triton X-100 (DRMs), whereas some soluble proteins are expressed in
extrasynaptic membranes (Abdi and Bennett, 2008; Carlin et al., 1980; Cooper et al.,
2000; Cotman et al., 1974; Ferrario et al., 2011a; Ferrario et al., 2011b; Goebel-Goody
et al., 2009). Proteins isolated from the AIS, lipid rafts and dendritic spines are often part
of the scaffolded signaling networks associated with these microdomains. Thus, it is
possible that long-term drinking is shifting Kv7.2 channels from extrasynaptic
membranes into specialized signaling domains, such as the AIS or dendritic spines
where the channels can influence neuronal excitability.
The possible mechanisms underlying Kv7.2 trafficking between membrane
microdomains during abstinence are not immediately clear. As discussed in Chapter 1,
there are multiple physical interfaces known to modulate Kv7 channel function.
Interaction with AKAP150 and SGK1 standout as the most likely candidates of these to
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regulate membrane trafficking (Delmas and Brown, 2005). However when we probed for
expression of these proteins in alcohol-exposed rats, we found no difference in their
expression compared to naïve animals. This suggests that Kv7.2 membrane trafficking
may be mediated by a different mechanism. A recent study suggests that SUMOylation
may play an important role in the regulation of Kv7 channel function (Qi et al., 2014).
Although SUMOylation was once thought to exclusively regulate nuclear transport,
several studies over the last decade indicate that this posttranslational modification plays
a key role in synaptic plasticity (Review: (Luo et al., 2013)).
Recent evidence suggests that SUMOylation of Kv2.1 and Kv7 channels
decreases K+-current where as de-SUMOylation increases their function, indicating that
SUMOylation state may regulate neuronal excitability (Dai et al., 2009; Plant et al., 2011;
Qi et al., 2014). SUMOylation is the covalent attachment of a small ubiquitin-like
modifying (SUMO) to a lysine residue via a series of proteins (E1-3; (Ren et al., 2009).
The SENP proteases are primarily responsible for the de-SUMOylation process. Studies
indicate that SUMOylated proteins and SUMO-related enzymes are enriched in
synaptosomes (Feligioni et al., 2009; Martin et al., 2007a; Martin et al., 2007b), and colocalize with pre- and postsynaptic membrane proteins (Jaafari et al., 2013; Martin et al.,
2007a; Plant et al., 2011). A recent study suggests that AMPA-induced depolarization of
neurons increases SUMOylation (Feligioni et al., 2009), and preventing SUMOylation
prevents synaptic insertion of AMPA receptors (Jaafari et al., 2013).
In our study, we searched the rat Kv7.2 peptide for the SUMOylation consensus
sequence and found multiple potential SUMOylation sites. Most noteworthy were the 6
sites on the C-terminus and the single site in the pore-forming intramembrane.
Modifications at the termini of membrane channels can directly affect protein trafficking
(Lu and Roche, 2012; Mao et al., 2011). This concept is true of Kv7.2, which is
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influenced by interaction of AKAP150 and CaM at the C-terminus (Delmas and Brown,
2005). Of the 6 SUMOylation sites found on the C-terminus of Kv7.2, two lie within the
AKAP150 and CaM binding regions of the terminus (Delmas and Brown, 2005).
AKAP150 directly interacts with the Kv7.2 subunit and PKC such that AKAP binds the
active site of the kinase, preventing phosphorylation-induced inhibition of M-current (Bal
et al., 2010; Hoshi et al., 2003). Thus SUMOylation could prevent the AKAP150-Kv7.2 or
Kv7.2-PKC interaction. CaM also directly interacts with the Kv7.2, and although its exact
role in Kv7 channel trafficking and function has yet to be defined (Etxeberria et al., 2008;
Gomez-Posada et al., 2011; Wen and Levitan, 2002), SUMOylation could alter channel
trafficking by preventing this interaction. Posttranslational modifications within or near
the Kv7.2 channel pore could potentially block ion conductance, leading to increased
excitability. Alternatively, a modification near the pore domain could induce a
conformational change in the channel leading to pore closure. Although this may not
directly affect channel trafficking, altered Kv7 channel function could initiate other
mechanisms to induce activity-dependent trafficking such as those observed with Kv4.2
channels (Kim et al., 2007) and AMPA receptors (Groc et al., 2004; Ju et al., 2004).
Our study showing alcohol-induced increased sensitivity to Kv7 channel blockade
suggests that the shift in trafficking patterns has a functional consequence on membrane
excitability. A recent study has shown that hyper-SUMOylation of Kv7 channels results in
a reduction in M-current not associated with changes in channel expression that leads to
deleterious hyperexcitable state (Qi et al., 2014). This suggests that SUMOylation
prevents current through Kv7 channels. Altogether, SUMOylation is a likely candidate
mechanism for regulating withdrawal-induced trafficking of Kv7.2. Indeed, withdrawal
from alcohol decreases the expression of SUMOylated Kv7.2 in DSM, and the ratio of
SUMOylated Kv7.2 to total Kv7.2 expression in the DRM. It is interesting to note that
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surface expressed Kv2.1 channels also move fluidly in and out of similar microdomains
within the plasma membrane (O'Connell et al., 2006), and that current through these
channels is affected by SUMOylation state (Dai et al., 2009; Plant et al., 2011; Qi et al.,
2014). Chronic alcohol exposure is known to produce activity-dependent homeostatic
neuroadaptations to counteract the inhibitory actions of ethanol (Mulholland and
Chandler, 2007), and activity-dependent processes alter Kv7.2 channel protein and
Kcnq2 transcript expression in hippocampus and amygdala (Penschuck et al., 2005;
Zhang and Shapiro, 2012). Furthermore, a recent study associated differential
expression of Kcnq2 as a candidate cis-eQTL for alcohol consumption and withdrawal
symptoms (Metten et al., 2014). Electrophysiology studies indicate that spike firing is
increased in the NAc 3-5 weeks after prolonged alcohol self-administration (Hopf et al.,
2010), and that MSNs in the NAc display increased mini-excitatory postsynaptic currents
and increased paired pulse ratios during withdrawal from prolonged alcohol exposure
(Marty and Spigelman, 2012a; Padula et al., 2015; Spiga et al., 2014). These studies
indicate that NAc neurons are more excitable during withdrawal. Although speculative,
our experiments suggest that during withdrawal, when cells are in a hyperexcitable state,
Kv7 channels in the membrane are de-SUMOylated and recruited to the signaling
networks where they can help regulate neuronal excitability.
In summary these studies indicate that prolonged alcohol consumption leads to
increased sensitivity to Kv7 channel blockade possibly resulting from the observed
adaptations in the Kv7 channel expression and SUMOylation state during alcohol
withdrawal. These studies are the first to show that Kv7 channel trafficking within the
plasma membrane can be affected by external stimuli, and provide the first direct
evidence that SUMOylation may regulate Kv7 channel expression.
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS
Conclusions
Alcohol use disorders (AUDs) represent a substantial social and economic
burden around the world. Current FDA-approved pharmacotherapies for AUDs are
efficacious in only a subset of individuals and suffer from deleterious side effects. It is
therefore essential to find improved medications for the management of these disorders.
The experiments described in this dissertation provide strong evidence for retigabine, an
FDA-approved anticonvulsant, as a pharmacotherapy for aiding in drinking cessation to
treat AUD. This work further describes a complex relationship between Kv7 channels
and alcohol-drinking behaviors that spans genetic variation, behavioral pharmacology,
and biochemical adaptations.
Results from the bioinformatics search described in Chapter 2 showed that
Kcnq2/3 contribute to an alcohol drinking phenotype across multiple strains of rodents.
The data suggest that Kcnq2 and Kcnq3 and their encoded proteins may be useful
pharmacogenetic targets to treat AUDs. The behavioral pharmacology studies in
Chapters 3 strengthened this relationship by showing that systemic administration
retigabine and the Kv7 channel-specific positive modulator ML-213 reduce alcohol
consumption in a long-term intermittent access model. Furthermore, in Chapter 4 we
showed that microinjections of retigabine to the ventral tegmental area (VTA) and
nucleus accumbens (NAc) core also reduce voluntary drinking. Notably, retigabine was
more effective at reducing drinking in Wistar rats with a heavy drinking phenotype. An
aberrant dopaminergic response is associated with prolonged alcohol exposure (Brodie,
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2002) and heavy drinking phenotypes (Bice et al., 2008; Bustamante et al., 2008;
Gongwer et al., 1989; Imperato and Di Chiara, 1986; Zhou and Palmiter, 1995). Given
that retigabine, unlike most other anticonvulsants, can alter dopamine (DA)
neurotransmission (Hansen et al., 2006; Koyama and Appel, 2006; Sotty et al., 2009),
these data suggest that retigabine may decrease alcohol consumption through
restoration of the DA response. In a clinical context, these experiments indicate both that
retigabine may be a promising candidate for treating AUDs and that Kv7 channel
function in key nodes of the addiction neurocircuitry regulates drinking behaviors.
In Chapter 5 we described experiments showing that long-term drinking
enhanced sensitivity to the pro-convulsant effects of Kv7 channel blockade and altered
surface trafficking of Kv7.2 channels between detergent resistant and soluble
membranes in the NAc. The surface trafficking was associated with reduced Kv7.2
channel SUMOylation in the DRM fraction. To our knowledge, these data are the first to
show evidence for post-translational modification by SUMOylation in a model of alcohol
or drug exposure. Repeated exposure to alcohol induces a hyperexcitable state in MSNs
of the NAc (Marty and Spigelman, 2012b; Padula et al., 2015; Spiga et al., 2014). Given
that hyper-SUMOylation of Kv7 channels reduces M-current (Qi et al., 2014), these
biochemical experiments suggest that Kv7 channel function may be dependent both on
localization within distinct microdomains in the plasma membrane and SUMOylation
state.
In summary the work described in this dissertation provide strong evidence for
the use of retigabine as a pharmacotherapy for the treatment of AUDs. Furthermore,
these data highlight Kv7 channels as targets of alcohol-induced neuroplasticity.
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Future Directions
Detailed discussions and interpretations of the results from the experiments
performed during this dissertation are provided within their individual chapters. However
some of these explanations warrant additional thought and further experimentation. The
following sections highlight future directions and experiments that would provide direct
insight to particular conclusions from this dissertation.

Kv7 Channel Trafficking, Alcohol Withdrawal, and Retigabine
One of the most exciting observations from this work is that withdrawal from longterm drinking in the IAA model induces a shift in Kv7.2 expression from detergent
soluble membrane (DSM) to detergent resistant membrane (DSM). Some plasma
membrane proteins found in the axon initial segment (AIS), lipid rafts, and dendritic
spines are insoluble in Triton X-100 (DRMs), whereas some soluble proteins are
expressed in extrasynaptic membranes (Abdi and Bennett, 2008; Arnsten et al., 2010;
Carlin et al., 1980; Cooper et al., 2000; Cotman et al., 1974; Ferrario et al., 2011a;
Ferrario et al., 2011b; Goebel-Goody et al., 2009). Proteins isolated from the AIS, lipid
rafts and dendritic spines are often part of the scaffolded signaling networks associated
with these microdomains. Thus, it is possible that long-term drinking is shifting Kv7.2
channels from extrasynaptic membranes into specialized signaling domains, such as the
AIS or dendritic spines where the channels can influence neuronal excitability. Studies
indicate that chronic alcohol exposure induces a hyperexcitable state in MSNs of the
NAc (Marty and Spigelman, 2012b; Padula et al., 2015; Spiga et al., 2014). The AIS is a
likely

candidate

microdomain

for

alcohol-induced

neuroplasticity

of

excitatory

mechanisms because it is the point of initiation an action potential (Harty et al., 2013)
and is enriched with Kv7 channels (Pan et al., 2006). Moreover, Kv7 channels in the AIS
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modulate spike initiation and adaptation (Cooper, 2011), and Kv7.2 co-assembly with
Kv7.3 is required for the recruitment of Kv7 channels to this region (Cooper et al., 2000).
The AIS is also susceptible to activity-dependent relocation relative to the soma in such
a manner as to regulate neuronal excitability in dissociated hippocampal cultures (Grubb
and Burrone, 2010). A recent study showed that hyper-SUMOylation of Kv7 channels
substantially decreased M-current (Qi et al., 2014). In our experiments, Kv7.2
SUMOylation in the NAc was decreased in the DSM fraction during withdrawal. Although
speculative, it is possible that during an alcohol withdrawal-induced hyperexcitable state,
Kv7 channels are de-SUMOylated and recruited to the signaling networks within the AIS
where they can help control aberrant excitability.
The ability of retigabine to reduce voluntary alcohol consumption could capitalize
on withdrawal-induced trafficking adaptations. In Chapter 4 we argued that microinfusion
of retigabine to the NAc core could reduce alcohol consumption by suppressing activity
and subsequent initiation of alcohol-seeking behaviors. In our experiments, retigabine is
administered 10-30 minutes prior to alcohol availability after a 24-hour withdrawal period
from the previous session. At this point, Kv7 channels may have already been recruited
to the AIS and other DRMs in the NAc to ease withdrawal-induced hyperexcitability
(Marty and Spigelman, 2012b; Padula et al., 2015; Spiga et al., 2014), making these
membranes particularly sensitive to the inhibitory effects of retigabine. Alternatively, if
24-hour withdrawal is not sufficient to alter Kv7 channel trafficking, retigabine could
simply stabilize membrane excitability by augmenting the function of the few channels
remaining in the AIS.
These hypotheses could be tested through a series of experiments using
immunohistochemistry (IHC) and electrophysiology. Specifically, tissue from the NAc
taken at 0, 24 and 72 hours withdrawal from IAA drinking could be fixed and probed for
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co-expression of Kv7.2 and ankyrin-G, a necessary component to AIS scaffolding
(Kordeli et al., 1995). If Kv7 channels are recruited to the AIS to regulate excitability, we
would predict greater co-expression of Kv7.2 and ankyrin-G during withdrawal compared
to alcohol-naïve rats. The role SUMOylation may be better visualized using an
alternative model of alcohol exposure because it is dependent on active processes
within the cell. No SUMO-Kv7 channel antibodies currently exist; therefore to capture
SUMOylation-related changes in channel trafficking, the system would need to be
treated with a SUMOylating enzyme (i.e. Ubc-9) or a de-SUMOylating enzyme (i.e.
SENP2) and then immediately fixed for IHC. However, drinking rats must be perfused
with PFA and before IHC, but organotypic hippocampal slice cultures (OHSCs) can be
chronically treated with cycles alcohol exposure and withdrawal, recapitulating some of
the biochemical adaptations seen in models of alcohol consumption (Mulholland et al.,
2011). We could induce the de-SUMOylation using the SENP enzyme process in
OHSCs and then immediately fix the tissue. IHC experiments could then be conducted
examining the co-expression of Kv7.2 and ankyrin-G in the AIS of pyramidal neurons.
We would predict that during withdrawal, de-SUMOylation process would recruit Kv7
channels to the AIS in naïve cultures in a manner similar to alcohol-exposed cultures.
The physiological relevance of alcohol-induced Kv7 channel trafficking could be
investigated using patch-clamp recordings of M-current within and immediately adjacent
to the AIS of MSNs in NAc tissue from IAA rats during various withdrawal time points.
The effects of retigabine on M-current could also be measured at these time points.
Furthermore, by treating the tissue with SENP2, we could potentially measure the
physiological relevance of SUMOylated Kv7 channels. Here we would predict that Mcurrent is increased in the AIS both compared to adjacent areas and compared to the
AIS of alcohol-naïve rats. Also, de-SUMOylating the channels should increase M-current
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in membrane adjacent to the AIS, regardless of the withdrawal time point. Both the IHC
and electrophysiological experiments were outside the scope of this dissertation, but
would provide valuable insight to alcohol-induced adaptations in Kv7 channel expression
and function.

Alternative Kv7 Channel Regulation
Experiments described in Chapters 3 and 4 we show that retigabine reduces
voluntary alcohol consumption both when administered systemically and when
microinfused into nodes of the addiction neurocircuitry. While altered DA transmission
likely represents the downstream effect of retigabine on the addiction neurocircuitry,
upstream activity is equally noteworthy. Antagonists of the peptide hormone ghrelin are
able to reduce alcohol consumption (Jerlhag et al., 2011; Landgren et al., 2008) and
there is an established role of ghrelin in multiple addictive substances (review:
(Panagopoulos and Ralevski, 2014)). Recent evidence indicates that ghrelin enhances
neuronal excitability by inhibiting Kv7 channels (Shi et al., 2013). Given the results of our
experiments, these studies suggest that the ability of ghrelin antagonists to reduce
drinking may ultimately be through an increase in Kv7 channel function, and that ghrelin
may be an upstream target of alcohol’s effect on Kv7 channel function.

Kv7 Channels and Alcohol Withdrawal Syndrome
In Chapter 5 we found that rats with a history of alcohol consumption are
susceptible to seizure-like activity induced by blocking Kv7 channels, which provided
evidence that prolonged drinking leads to changes in Kv7 channel function and/or
expression. Although convulsant activity is a symptom of alcohol withdrawal syndrome
(AWS) (Bayard et al., 2004), the IAA paradigm has not been previously reported to
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induce such symptoms in rats. As previously mentioned, there is indeed a shift in Kv7.2
expression from DSM to DRM in the NAc during withdrawal that has the potential to
affect neuronal excitability and behaviors. To date, M-current has only been recorded
from dopaminergic neurons in response to acute bath application of alcohol (Koyama
and Appel, 2006). We hypothesize that during withdrawal from prolonged IAA drinking,
M-current would be elevated compared to naïve controls, however, studies to quantify
changes in Kv7 channel expression and M-current in regions critical to seizure
generation (i.e. the hippocampus and amygdala) (Engel, 1995) would provide a better
understanding of the convulsant activity associated with alcohol withdrawal syndrome.

Individual Differences, Retigabine, and Alcohol
One of the key findings in this dissertation is that retigabine reduces voluntary
alcohol consumption when systemically injected and when microinfused to the NAc and
VTA of high drinking rats but not low drinking rats (Chapters 3 and 4). Numerous studies
have observed quantifiable characteristics associated with drinking behaviors in cohorts
of outbred rat strains. Wistar rats in a choice drinking paradigm were divided into high (~
4.2 g/kg/24 hrs) and low drinking (~ 2.1 g/kg/24 hrs) subpopulations (Momeni and
Roman, 2014). In addition, alcohol consumption in Long Evans rats is predictive of
anxiety-like behaviors (Hayton et al., 2012). Multiple inbred rodent inbred strains have
been generated to either prefer or avoid alcohol. Two strains P (alcohol preferring) and
NP (non-preferring) were derived from the outbred Wistar strain (Waller et al., 1983).
These strains represent the extreme ends of the continuum of drinking observed in the
cohorts used in our studies, and have less genetic variation compared to their outbred
parent strain (Funk et al., 2006). Consequently, these strains more definitively represent
high and low drinking populations, and using them in the IAA model would provide an
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alternative to measuring the effect of retigabine on high and low drinking rats. Given that
retigabine decreased alcohol consumption in high drinking Wistar rats and increased
consumption in the low drinking population, we would expect similar results of systemic
retigabine in P and NP strains. The microinjection studies could also be replicated in P
and NP rats to provide further insight into the role of Kv7 channel function in high and
low drinking populations.
Using selectively-bred high and low preferring strains to measure the efficacy of
retigabine on drinking would provide insight into the two ends of the drinking spectrum,
however the BXD strains of mice would provide an opportunity to examine the spectrum
of alcohol consumption in mice with different drinking phenotypes. C57BL/6 mice are an
alcohol-preferring strain whereas the DBA mice avoid alcohol. Studies indicate that
C57BL/6 mice drink more in 2-bottle choice paradigms (Meliska et al., 1995; Rhodes et
al., 2007) and short-access models (Belknap et al., 1997; Le et al., 1994), and that DBA
mice are less sensitive to alcohol-induced locomotor sensitization (Kiianmaa and
Tabakoff, 1983). Numerous recombinant inbred (RI) strains have been developed from
interbreeding the C57BL/6J and DBA/2J strains. These mice, referred to as “BXD”
strains, represent continuum of alcohol phenotypes that strongly correlate to their
genetic composition (DuBose et al., 2013; Mulligan et al., 2006; Padula et al., 2015;
Vanderlinden et al., 2013). By exposing the parent strains (C57BL/6 and DBA) and a
selection of BXD strains from across the drinking spectrum to the IAA paradigm, we
would be able to precisely investigate the effects of retigabine on populations with
different dispositions to consume alcohol. We predict that the reduction in drinking by
retigabine would be more effective in high drinking BXD strains. Similarly, increased
consumption by retigabine would diminish as we move from non-preferring to preferring
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strains. In the middle of this spectrum of drinkers we would predict no effect of retigabine
on drinking.
Several studies have also identified a strong correlation between individual
differences in drinking with differences in anxiety. A recent study grouped Long Evans
rats into high anxiety and low anxiety groups, and found that the high anxiety group
voluntarily consumed more alcohol compared low anxiety rats from the same cohort
(Hayton et al., 2012). Finally, high anxiety in Wistar rats in an elevated plus maze was
predictive of high anxiety in other models (Ho et al., 2002). These studies suggest that
high drinking rats are prone to higher levels of anxiety, and that alcohol consumption
may alleviate that anxiety. Chronic stress can increase anxiety-like behavior in multiple
strains of mice (Kim and Han, 2006; Mineur et al., 2006), and repeated exposure to
stressors is known to increase alcohol consumption (Becker et al., 2011). This suggests
a correlation between anxiety and alcohol consumption, and retigabine is known to have
anxiolytic effects. Specifically, retigabine and other Kv7 channel positive modulators
reduce anxiety-like behaviors associated with a zero maze in mice (Blackburn-Munro
and

Jensen,

2003;

Korsgaard

et

al.,

2005).

Furthermore,

newer-generation

anticonvulsants (e.g. gabapentin and lamotrigine) are often prescribed as off-label
treatments for patients with anxiety disorders, which like epilepsy, are characterized by
overactive neuronal activity (Blackburn-Munro et al., 2005). In our drinking model we
anecdotally observed some anxiety-like behaviors (i.e. excessive forearm grooming and
porphyrin staining), however we did not formally assess these behaviors. It would also
be interesting to examine the effects of retigabine on anxiety associated with alcoholwithdrawal. It is possible that the ability of retigabine to reduce drinking is mediated
through a combination dopaminergic, anxiolytic, and anticonvulsant mechanisms.
Although outside the scope of this project, this possibility warrants further investigation.
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Dopamine Release in the IAA Model
As previously mentioned, we observed individual differences in the efficacy of
retigabine in high and low drinking rats from the same cohort. Of particular interest was
that retigabine reduced alcohol consumption when microinfused to the NAc and VTA in
high drinking rats but had no effect on drinking when administered to low drinking rats
(Chapter 4). Individual differences such as these likely relate to slight genetic variation
within the cohort, and studies investigating inbred rat strains specifically selected to
prefer or avoid alcohol have found numerous dopaminergic discrepancies. Compared to
alcohol-avoiding strains, alcohol-preferring rats have decreased Drd2 mRNA expression
in the NAc (Bice et al., 2008; Imperato and Di Chiara, 1986), a lower baseline level of
DA in the ventral striatum (Gongwer et al., 1989; Zhou and Palmiter, 1995), and an
increased dopaminergic response to acute alcohol (Bustamante et al., 2008). These
studies indicate that, under basal conditions, alcohol-preferring rats have an aberrant DA
tone.
Given that retigabine can alter DA neurotransmission (Hansen et al., 2008;
Koyama and Appel, 2006; Sotty et al., 2009), we argue that retigabine reduces alcohol
consumption by restoring dopaminergic tone. This could be directly tested through
microdialysis experiments. Specifically, dopamine release could be measured in the NAc
during the first several hours of drinking in the IAA paradigm after systemic retigabine
was administered. Such an experiment would provide two highly interesting pieces of
information. The first would be to better elucidate the mechanism through which
retigabine reduces alcohol consumption. The second would be to provide insight into the
DA response during voluntary drinking in the IAA paradigm. To our knowledge, most
microdialysis studies measuring DA response to alcohol in drinking rats have either been
completed in operant administration models (Melendez et al., 2002; Weiss et al., 1993)
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or after an intoxicating IP dose of alcohol (Feduccia et al., 2014; Soderpalm et al., 2000;
Steensland et al., 2012). We found one study measuring accumbal DA in a continuous
access choice drinking model for 6% alcohol and DA was only collected for 60 minutes
after alcohol availability (Ericson et al., 1998). Such an experiment in our IAA model is
beyond the current project, but would provide valuable knowledge. Given the critical
nature of DA release from the VTA to the NAc in addiction processes and the ability of
retigabine to modulate this release, experiments to directly investigate the relationship
between retigabine, drinking, and DA will be a major focal point in future studies.

The work presented in this dissertation illustrates an intricate relationship between Kv7
channels and alcohol consumption spanning genetic variation, pharmacology, and
biochemical adaptations. Genetic meta-analysis demonstrated that Kcnq2/3 contribute to
an alcohol drinking phenotype and alcohol-related behaviors in rodents. Behavioral
pharmacology experiments indicate that positive modulation of Kv7 channels both
systemically and in key nodes of the addiction neurocircuitry can reduce voluntary
alcohol consumption. Furthermore, this effect is dependent on individual differences and
observed in rats with a heavy drinking phenotype. Finally, Kv7 channels in the NAc are
susceptible to alcohol-induced neuroadaptations and posttranslational modification, as
evidenced by biochemical assays. Together, these experiments support retigabine as a
potential pharmacotherapy for the treatment of AUD, and highlight Kv7 channels as
mediators of alcohol-related behaviors as well as targets of alcohol-induced
neuroadaptations.
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Figure A.2 | A visual representation of the hierarchy of individual genes common to multiple gene sets identified by
GeneWeaver that contain Kcnq2. Gene sets are listed in bold in each box. The number of genes or specific gene names that
are contained within those gene sets are listed in plain text. Connecting lines link sets that are completely contained within each
other. GeneWeaver GeneSet ID #: 1: GS1140, 2: GS216898, 3: GS34243, 4: GS135282, 5: GS84137, 6: GS35466, 7: GS84141,
8: GS3647, 9: GS3507, 10: GS84140, 11: GS135281, 12: GS84142, 13: GS84143
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Figure A.2 | A visual representation of the hierarchy of individual genes common to multiple gene sets identified by
GeneWeaver that contain Kcnq3. Gene sets are listed in bold in each box. The number of genes or specific gene names that
are contained within those gene sets are listed in plain text. Connecting lines link sets that are completely contained within each
other. GeneWeaver GeneSet ID #: 1: 135133, 2: 135132, 3: 84286, 4:14929, 5: 84284, 6: 37147, 7: 135223, 8: 115112, 9:
115114, 10: 115115, 11: 115116, 12: 11511, 13: 115121, 14: 75567
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Appendix&Figure&A.3&
1,#2,#3,#4,#5#
41#Genes#

1,#2,#3,#4#
108#Genes#

1,#2,#4,#5#
166#Genes#

1,#2,#4#
365#Genes#

1,#2,#5#
167#Genes#

2,#4,#5#
169#Genes#

1,#3#
114#Genes#

1,#2#
366#Genes#

2,#4#
369#Genes#

2,#5#
170#Genes#

3#
115#Genes#

1#
475#Genes#

2#
370#Genes#

5#
305#Genes#

Figure A.3 | A visual representation of the hierarchy of individual genes
common to multiple gene sets identified by GeneWeaver that contain Kcnq3.
Gene sets are listed in bold in each box. The number of unique genes or specific
gene names that are contained within those gene sets are listed in plain text.
Connecting lines link sets that are completely contained within each other.
GeneWeaver GeneSet ID #: 1: 84098, 2: 84097, 3: 135279, 4: 84096, 5: 84101
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